Randomized, Multi-center, Double-blind, Two-armed, Parallel Active Groups, Prospective Trial, to Evaluate, in Pediatric Population, the Efficacy and Safety of Chloroprocaine 1% and 2% for Peripheral Nerve Block.
Phase: PHASE2
Conditions: Hernia, Inguinal, Flat Foot
Sponsor: Sintetica SA

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
1 
 
 
 
CLINICAL STUDY PROTOCOL 
 
STUDY TITLE: 
Randomized, multi-center, double-blind, two-armed, parallel active groups, prospective trial, 
to evaluate, in pediatric population undergoing 'Calcaneo stop' surgery or Inguinal hernia 
repair, the efficacy and safety of chloroprocaine 1% and 2% for peripheral nerve block based 
on concentration–response relationships. 
 
 
EudraCT Number: 2018-000656-18 
Test Product:  
 
Chloroprocaine HCl 2% injection (20 mg/mL), Sintetica S.A., Switzerland 
 
Sponsor: SINTETICA SA, Via Penate 5, 6850 Mendrisio (Switzerland) 
 
Clinical Phase: Phase II 
 
Protocol Version Date:Final Version 1.0, 14June2018 
 
 
Study Manager: Erika Botti 
 
 
Coordinating Center:Regina Margherita Children’s Hospital – Division of Paediatric Aenesthesiology & 
Intensive Care - Torino (Italy) 
 
Principal Investigator: Prof. Giorgio Ivani, Chairman, Division of Paediatric Aenesthesiology & Intensive 
Care, Regina Margherita Children’s Hospital - Torino (Italy) 
 
CRO: L.N.Age srl., via Luigi Rizzo, 62, 00136 Roma (Italy) , Scientific Director Dr. Paolo Ferrazza 
 
This clinical study will be conducted in accordance with the sponsor's Standard OperatingProcedures 
(SOPs), current Good Clinical Practice (GCP), the provisions of ICH(International Conference on 
Harmonisation) Guidelines and EU Directives 
 
CONFIDENTIAL 
The information in this document is considered privileged and confidential, and may not bedisclosed to 
others except to the extent necessary to obtain Institutional Review Board/EthicsCommittee approval, 
informed consent and the approval of local regulatory authorities asrequired by local law. 
 
 
 
 
 
 
 
Chloroprocaine HCl 1% injection (10 mg/mL), Sintetica S.A., Switzerland

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
2 
 
Table of Contents 
 
1. PROTOCOL SYNOPSIS .............................................................................................................................. 6 
1.1 
Study Flow Chart ............................................................................................................................. 12 
2. INTRODUCTION ....................................................................................................................................... 14 
2.1 
Background information .............................................................................................................. 14 
2.1.1 
Premise .................................................................................................................................... 14 
2.1.2 
Local anaesthesia and PNB ..................................................................................................... 14 
2.1.3 
Chloroprocaine ........................................................................................................................ 14 
2.1.4 
Safety of local anaesthetics ...................................................................................................... 15 
2.1.5 
Chloroprocaine use in pediatric population ............................................................................. 16 
2.1.6 
Ultrasound-guided PNB in children ........................................................................................ 17 
2.2 
Study rationale ............................................................................................................................. 17 
2.3 
Risks and benefits ........................................................................................................................ 18 
2.3.1 
Risks ........................................................................................................................................ 18 
2.3.2 
Benefits .................................................................................................................................... 18 
3. STUDY OBJECTIVES ............................................................................................................................... 19 
3.1 Primary Objective .................................................................................................................................. 19 
3.2 Secondary Objectives ............................................................................................................................ 19 
4. STUDY DESIGN ........................................................................................................................................ 20 
4.1 
Study overview and plan ................................................................................................................. 20 
5. STUDY POPULATION .............................................................................................................................. 21 
5.1 
Number of Patients .......................................................................................................................... 21 
5.2 
Inclusion Criteria ............................................................................................................................. 21 
5.3 
Exclusion Criteria ............................................................................................................................ 22 
6. 
CRITERIA AND PROCEDURE FOR RANDOMIZATION ................................................................. 22 
6.1 
Treatment allocation ........................................................................................................................ 22 
6.2 
Blinding ........................................................................................................................................... 23 
6.3 
Emergency unblinding ..................................................................................................................... 23 
7. 
STUDY CONDUCT ............................................................................................................................... 24 
7.1 
Study Duration ................................................................................................................................. 24 
7.2 
Detailed Study Plan ......................................................................................................................... 24 
7.2.1 
VISIT V1: Screening phase ..................................................................................................... 24 
7.2.2 
VISIT V2: Surgery and Discharge (Day1) .............................................................................. 24 
7.2.3 
TELEPHONE FOLLOW UP VISITS ..................................................................................... 25 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
3 
 
8. 
TRIAL PROCEDURES AND ASSESSMENTS .................................................................................... 25 
8.1 
Physical examination and vital signs ............................................................................................... 25 
8.2 
Electrocardiogram ........................................................................................................................... 26 
8.3 
Sensory block assessment ................................................................................................................ 26 
8.4 
Motor block assessment................................................................................................................... 27 
8.5 
Post-surgery pain intensity .............................................................................................................. 27 
8.5.1 
COMFORT scale for patients aged < 2 months of age ........................................................... 27 
8.5.2 
FLACC scale for patients aged    2 months  6 years ........................................................... 28 
8.5.3 
Wong-Baker scale for patients over 6 years of age ................................................................. 28 
8.5.4 
Pediatric Post Anesthesia Discharge Scoring System (Ped-PADSS) ...................................... 28 
8.6. 
Post-discharge assessments ............................................................................................................. 28 
9. 
STUDY DRUG ....................................................................................................................................... 29 
9.1 
Study Drugs Description ................................................................................................................. 29 
9.2 
Dosage and administration .............................................................................................................. 29 
9.3 
Packaging and Labeling................................................................................................................... 30 
9.4 
Accountability And Compliance ..................................................................................................... 30 
9.5 
IMP dispensing to patients .............................................................................................................. 30 
9.6 
Other drugs to be used in the study ................................................................................................. 30 
9.6.1. 
Premedication before surgery .................................................................................................. 30 
9.6.2. 
Rescue anesthesia during surgery ............................................................................................ 31 
9.6.3. 
Rescue analgesic treatment ...................................................................................................... 31 
9.7 
Concomitant medications ................................................................................................................ 31 
9.7.1. 
Allowed medications ............................................................................................................... 31 
9.7.2. 
Not allowed medications ......................................................................................................... 31 
10. 
SAFETY AND PHARMACOVIGILANCE ....................................................................................... 31 
10.1 
Adverse Event definition ................................................................................................................. 32 
10.2 
Serious Adverse Event..................................................................................................................... 32 
10.3 
Adverse Event Reporting Period ..................................................................................................... 32 
10.4 
Recording of Adverse Events .......................................................................................................... 32 
10.5 
Reporting of Serious Adverse Events .............................................................................................. 33 
11. 
STATISTICAL METHODOLOGY .................................................................................................... 33 
11.1 
Rationale for sample size calculation .............................................................................................. 33 
11.2 
Study endpoints ............................................................................................................................... 34 
11.2.1 
Primary efficacy endpoint ....................................................................................................... 34 
11.2.2 
Secondary efficacy endpoints .................................................................................................. 34 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
4 
 
11.2.3 
Secondary safety endpoints ..................................................................................................... 35 
11.3 
Analysis sets .................................................................................................................................... 35 
11.4 
Description of statistical analysis .................................................................................................... 35 
11.4.1 
Handling of missing data ......................................................................................................... 35 
11.4.2 
Primary efficacy variable ......................................................................................................... 35 
11.4.3 
Secondary efficacy variables ................................................................................................... 35 
11.4.4 
Safety variables........................................................................................................................ 36 
11.5 
Interim Analysis .............................................................................................................................. 36 
12. 
REGULATORY AND ETHICAL ISSUES ........................................................................................ 36 
12.1 
Compliance With Regulations Applicable To Clinical Trials ......................................................... 36 
12.2 
Informed Consent and Child Assent Form ...................................................................................... 36 
12.3 
Criteria for patient’s withdrawal ...................................................................................................... 37 
12.4 
Withdrawal from the Investigational Medicinal Product ................................................................ 37 
12.5 
Premature discontinuation of the trial ............................................................................................. 37 
12.6 
Definition of end of the trial ............................................................................................................ 37 
12.7 
Regulatory Authorities and Ethics Committee (EC) ....................................................................... 38 
12.8 
Protocol Amendments ..................................................................................................................... 38 
12.9 
Patient Confidentiality ..................................................................................................................... 38 
12.10 
Clinical Trial Insurance ............................................................................................................... 38 
13. 
DOCUMENTATION .......................................................................................................................... 38 
13.1 
Site Documents Required ................................................................................................................ 38 
13.2 
Site Documents Supplied By The Sponsor ...................................................................................... 39 
13.3 
Maintenance And Retention Of Records ......................................................................................... 39 
13.4 
Case Report Form (Crf) ................................................................................................................... 39 
13.5 
Source Data and Subject Files ......................................................................................................... 39 
13.6 
Monitoring ....................................................................................................................................... 40 
13.7 
Protocol Modifications .................................................................................................................... 40 
13.8 
Audit/Inspection .............................................................................................................................. 40 
14. 
USE OF INFORMATION AND PUBLICATION ............................................................................. 41 
14.1 
Confidential Information ................................................................................................................. 41 
14.2 
Clinical Trial Report ........................................................................................................................ 41 
14.3 
Publication policy ............................................................................................................................ 41 
15. 
INVESTIGATOR’S AGREEMENT ................................................................................................... 42 
16. 
REFERENCES .................................................................................................................................... 43 
17.  
LIST OF APPENDICES ..................................................................................................................... 45 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
5 
 
List of abbreviations  

 
AE 
Adverse Event 
ASA 
American Society of Anesthesiologists  
CI 
Confidence Interval 
EC 
Ethics Committee 
ECG 
Electrocardiogram 
e-CRF 
Electronic Case Report Form 
FLACC 
Face, Legs, Activity, Crying and Consolability 
GA 
General Anesthesia 
HCl 
Hydrochloride 
ICH 
International Conference on Harmonization 
IMP 
Investigational Medicinal Product 
IVRA 
Intravenous Regional Anaesthesia 
LA 
Local Anesthetic 
LAST 
Local Anaesthetic Systemic Toxicity 
LLT 
Low Level Term 
MedDRA 
Medical Dictionary for Regulatory Activities 
PNB 
Peripheral Nerve Block 
RA 
Regional Anesthesia 
SAE 
Serious Adverse Event 
SOC 
System Organ Class 
SOP 
Standard Operating Procedure 
USA 
United States of America 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
6 
 
1. PROTOCOL SYNOPSIS 
 
Title of the study: 
Randomized, multi-center, double-blind, two-armed, parallel active groups, prospective trial, to 
evaluate, in pediatric population undergoing 'Calcaneo stop' surgery or Inguinal hernia repair, the 
efficacy and safety of chloroprocaine 1% and 2% for peripheral nerve block (PNB) based on 
concentration–response relationships. 
EudraCT number: 
2018-000656-18 
Protocol code: 
CHL.2/04-2015 
Sponsor: SINTETICA SA, Via Penate 5, 6850 Mendrisio, Switzerland 
Study center(s): 
A total number of  7 clinical sites spread across Italy (5) and Spain (2) will take part in the trial. The 
coordinating site site will be in Italy. All details about the recruiting centers are reported in the 
comprehensive list provided separately from the present document 
Planned study period: 
June 2018– July 2020(Recruitment period: 24 months) 
Phase of Development: Phase II 
Name of Investigational Product:  
Chloroprocaine HCl 1% injection and Chloroprocaine HCl 2% injection  
Name of Active Ingredient: Chloroprocaine Hydrochloride 
Indication: Local anaesthesia by peripheral nerve block (PNB) 
Background and Rationale: 
The present protocol is part of an extensive Pediatric Investigational Plan (PIP) which has been 
submitted to the Paediatric Committee (PDCO) of the European Medicine Agency (EMA)in the 
contest of the marketing authorization application of chloroprocaine use for perineural block. 
The PDCO has adopted a positive opinion on both the PIP and the present clinical protocol. 
Chloroprocaine Hydrochloride 1% Sintetica is currently marketed in 9 European countries as 
intrathecal (spinal) anesthetic in adults where the planned surgical procedure is not expected to 
exceed 40 minutes. Since 2015, the Marketing Authorization in Switzerland has been extended to 
chloroprocaine HCl 20 mg/mL and 30 mg/mL solutions for injection, for local anesthesia by 
infiltration, for PNB and epidural block, respectively. 
Regional analgesia, and specifically PNB, is an acceptable means of providing intraoperative 
anesthesia and postoperative analgesia in neonates, infants, and children while decreasing the use of 
systemic opioids and avoiding opioid-related adverse effects. With the advent of ultrasound and 
improvements in equipment in the last decade, the utilization of PNB in children has increased 
tremendously. 
Calcaneo stop and inguinal hernia repair have been considered the ideal surgeries for testing the 
clinical efficacy and safety of chloroprocaine since they are short procedures with low 
postoperative pain that only require a short- to intermediate-acting agent. 
Objectives: 
Primary Objective 
The primary objective of the study is the assessment of the efficacy of chloroprocaine 1% and 2%, 
administered by perineural, ultrasound-guided, injection in pediatric population for a successful 
peripheral nerve block (same volume ml/Kg) in terms of proportions of subjects not requiring rescue 
anesthesia during surgery. 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
7 
 
Secondary Objectives 
Efficacy: 
• 
time to onset of sensory block starting from completion of the Investigational Medicinal 
Products IMPs injection (corresponding to readiness for surgery), detected by pin-prick in case 
of Inguinal hernia repair (ileogastric/ileoinguinal nerve block).The response to pinprick in 
sedated patient will be associated to at least a 20% increase from baseline in heart rate (HR). 
The sensory block onset will be achieved if no apparent hemodynamic reaction to pinprick 
will be seen (defined as an increase in heart rate in excess of 20% compared with baseline 
levels), meaning that the patient is ready for surgery. 
• 
time to onset of sensory block starting from completion of the IMPs injection (corresponding 
to readiness for surgery), detected by pin-prick test, in case of ‘calcaneo stop’ (sciatic nerve 
block). The response to pinprick in sedated patient will be associated to at least a 20% increase 
from baseline in heart rate (HR). The sensory block onset will be achieved if no apparent 
hemodynamic reaction to pinprick will be seen (defined as an increase in heart rate in excess 
of 20% compared with baseline levels), meaning that the patient is ready for surgery. 
• 
time to regression of motor block (sciatic nerve block) by standard Bromage scale, at the start 
of patient’s awakening, in case of calcaneo stop procedure. This phase will have to be 
monitored with particular care since events of agitation followed by numbness are very 
common in children after sevoflurane anesthesia. 
• 
pain intensity, assessed five times in the first 3 hours after the end of surgery and during the 
home discharge visit (V2). Post-surgery assessment will be performed immediately at 
awakening and 30 minutes, 1 hour, 2 hours and 3 hours after this first evaluation.  The 
following tools will be used for pain evaluation: COMFORT scale for patients <2 months of 
age, FLACC scale for patients aged  2 months  6 years, and Wong-Baker scale for patients 
over 6 years of age, respectively; 
• 
Time to eligibility for home discharge defined as: “the time elapsed from completion of 
surgery to the time when criteria for discharge are met, regardless if the patient will be 
discharged from the hospital at a later time, according to the hospital procedures”. The criteria 
for discharge will be defined according with the Pediatric Post Anesthesia Discharge Scoring 
System (Ped-PADSS) 
• 
if rescue anaesthesia (fentanyl) was required during both surgical procedures performed; 
• 
time and dosage of rescue anaesthesia (fentanyl) required during surgery, in addition to 
IMPsinjection; 
 
Safety: 
The secondary, safety objectives of the trial will be to assess:  
• 
the general tolerability and safety of the study drug, assessed through summaries of adverse 
events; 
• 
pain at injection site, neurological symptoms (such as: convulsions) and cardiac symptoms 
(such as bradycardia and heart failure etc.) evaluated during surgery after IMP injection. 
Study design: 
This is a prospective, randomized, multicenter, double blind, parallel active groups, concentration-
response model in pediatric population since birth to <18 years of age, phase II clinical trial.The study 
consists of a treatment period of 1 day and of a single perineural injection, administered through 
ultrasound-guided technique in order to avoid the risk of chloroprocaine IV injection. 
Planned number of patients: 
A total of 174 (87 per treatment group, allocated to 1% or 2% arm in a ratio of 1:1) male and female 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
8 
 
paediatric patients (age range from birth to <18 years) undergoing 'Calcaneo stop' surgery or Inguinal 
hernia repair, planned for peripheral nerve block anaesthesiaand equally distributed within the two 
surgical procedures.  
Inclusion criteria: 
1. Male and femalepaediatric patients from birth to <18 years scheduled for: 
- 'calcaneo stop' surgery  (6 to <18 years; children and adolescents)planned for sciatic 
nerve block short-lasting anaesthesia, 
- inguinal hernia repair (0 to 6 years; newborn infants, infants-toddlers and 
children)planned for ilioinguinal/iliohypogastric block  short-lasting anaesthesia; 
2. Normally active and otherwise judged to be in good health on the basis of medical history, 
physical examination, with normal lean body mass (BMI18,5 – 24,9 Kg/m2 inclusive) and 
normal body development (normal weight and height according to local paediatric Height 
and Weight Chart); 
3. ASA I and ASA II patients 
4. Written informed consent provided by parents/tutor, willing and able to understand the 
purpose of the study, including possible risks and side effects, and willing and able to 
comply, on their behalf and of the minor, with the study requirements. 
5. Willing and able to give additional written informed consent by itself, in case of children and 
adolescents, in addition to parents/tutor. 
6. Willing and able, in case of children and adolescents, to comply with the study requirements 
on their behalf.  
Exclusion criteria: 
1. ASA > II patients 
2. Preexistent infection at injection site; 
3. Use of opioids, antidepressants, anticonvulsant, sulfonamide, vasopressors,  ergot-type 
oxytocic drug and mixtures of local anaesthetics, antiarrhythmic drug class III, such as 
amiodarone, strong inhibitors of CYP1A2, such as fluvoxamine and enoxacin; 
4. Use of medication(s) known to interfere with the extent of regional blocks for 2 weeks before 
the start of the study; 
5. History of drug or alcohol abuse; 
6. Sensitivity among the study medication active ingredient, the members of the PABA esters 
group and amides-type local anesthetic group; 
7. Clinical history of allergy, hypersensitivity or intolerance to the study medication or other 
medications used during surgery; 
8. Pregnancy and lactation: positive pregnancy test at screening (if applicable), pregnant or 
lactating (the pregnancy test will be performed to all fertile subset)  
9. Participation in any other clinical study within the 3 months prior to the screening. 
Investigational medicinal product (IMP), dose and mode of administration: 
Chloroprocaine 
HCl 
(benzoic 
acid, 
4-amino-2-chloro-2-(diethylamino) 
ethyl 
ester, 
monohydrochloride) aqueous solutions for injection in two different concentrations, i.e.: 
a) Chloroprocaine Hydrochloride 1%: (10 mg/mL);  injectable solution, Sintetica S.A., 
Switzerland, 5 ml ampoules 
b) Chloroprocaine Hydrochloride 2%: (20 mg/mL);  injectable solution, Sintetica S.A., 
Switzerland, 20 ml vials 
Duration of treatment: 
1 day, a single, perineural, ultrasound-guided injection. 
Pre-medication before surgery: 
Patients will be pre-treated with: 
- 
Midazolam: will be administered orally, only in patients > 6 months of age, 45 min before 
surgery,according to local routine practice.  
- 
Sevoflurane by inhalation will be given, as recommended by local routine practice, in order to 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
9 
 
induce general anaesthesia, after midazolam sedation and before IMP administration. Patients 
will breath unaided and, unless necessary as an emergency measure, they are not supposed to 
be intubated in the frame of this preoperative procedure.  
 
Concomitant Medication after surgery:  
- 
Paracetamol 15 mg/kg, will be injected  i.v. immediately at the end of the surgery 
Rescue anaesthesia during surgery: 
Sensory block will be assessed by pin-prick test after chloroprocaine injection.  In case of incomplete 
sensory block (when readiness for surgery not reached),fentanyl by IV injectionwill be given,at the 
dosage indicated by local routine practice, as rescue anaesthesia. All details about the administration 
of the rescue anesthesia will have to be recorded on the relevant CRF.  
Permitted/Non permitted Concomitant Medications 
Not allowed medications: 
1. Vasopressors; 
2. Ergot-type oxytocic ; 
3. Sulphonamides;  
4. Mixtures of local anaesthetics;  
5. Opioids;  
6. Antidepressants; 
7. Anticonvulsants;  
8. Antiarrhythmic drug class III, such as amiodarone; 
9. Strong inhibitors of CYP1A2, such as fluvoxamine and enoxacin. 
 
Rescue medication: 
Paracetamol, oral or suppository, at home (after home discharge) 
Allowed medications:  
Hormonal contraceptives for females of childbearing potential. 
Treatment Compliance 
Not applicable 
Criteria for evaluation: 
 
Primary efficacy endpoint: 
The primary efficacy endpoint of the study will be represented by the overall proportion of patients, 
in each of the two dosage level groups, not requiring rescue anesthesia during surgery. 
 
Secondary efficacy endpoints: 
The secondary efficacy endpoints of the trial will be evaluated, unless otherwise specified, on the two 
dosage level groups separately and, in both the two dosage level groups, on the two surgical 
procedures. Secondary efficacy endpoints will be: 
• 
Proportion of patients, in both of the two dosage level groups, not requiring rescue 
anaesthesia (fentanyl) during the two surgical procedures separately;  
• 
Time to onset of sensory block, defined as the time period from completion of the 
injection (time 0 min) to the achievement of complete sensory block, assessed by pin-
prick test associated with heart rate measurement, and evaluated for both surgeries; 
• 
Time to regression of motor block evaluated in ‘calcaneo stop’ surgery only and 
assessed by a grade I of the standard Bromage scale (i.e. free movement of legs and 
feet). This evaluation will be performed immediately after the awakening and it will be 
repeated 30 minutes, 1 hour, 2 hours and 3 hours after the first evaluation, as well as 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
10 
 
during the visit for discharge  
• 
Pain intensity evaluated five times in the first 3 hours after patient’s awakening and 
during the home discharge visit (V2). Post-surgery assessment will be performed 
immediately after the awakening and it will be repeated 30 minutes, 1 hour, 2 hours and 
3 hours after the firstevaluation. The technique and appropriate scale for pain 
measurement are age-dependent therefore, different tools will have to be used for the 
evaluation: 
− 
COMFORT scale for patients <2 months of age; 
− 
FLACC scale for patients aged  2 months  6 years; 
− 
Wong-Baker scale for patients over 6 years of age;  
• 
Time to eligibility for home discharge, defined as: “the time elapsed from completion of 
surgery to the time when criteria for discharge are met, regardless if the patient will be 
discharged from the hospital at a later time, according to the hospital procedures”. The 
criteria for discharge will be defined according with the Pediatric Post Anesthesia 
Discharge Scoring System (Ped-PADSS) 
• 
Time from completion of IMP injection to rescue anaesthesia, whenever required 
• 
Posology of rescue anaesthesia, whenever required 
• 
Proportion of patients requiring additional analgesia after surgery, other than 
paracetamol 15 mg/kg i.v. administered during the surgery as per hospital’s standard 
procedures 
• 
Type and posology of rescue analgesia required during the 7 days after surgery for each 
one of the two surgical procedures 
 
Secondary safety endpoints: 
The secondary safety endpoints of the trial will be evaluated on the two dosage level groups 
separately and, in both the two dosage level groups, on the two surgical procedures, and will be: 
• 
Patient general recovery, evaluated by the Investigator through the evaluation questionnaire on 
the day of the intervention  
• 
Patient general recovery, evaluated by the Investigator or his deputy through the F.U 24 H 
evaluation questionnaire on the day after intervention  
• 
Patient general recovery, evaluated by the Investigator or his deputy through the F.U 7-day 
evaluation questionnaire 7 days after intervention  
• 
Overall proportion and 95% CI of patients with prolonged post-operative temporary loss of 
sensation and/or motor activity 
• 
Vital signs at rest (heart rate, systolic/diastolic blood pressure, respiratory rate, body 
temperature) 
• 
Proportion of patients with AE, in each of the two dosage level groups and in the two surgical 
procedures  
• 
Summaries of adverse events (AEs), including pain at injection site, neurological 
symptoms(such as: convulsion) and cardiac symptoms (such as bradycardia and heart failure 
etc.) evaluated, during surgery, after IMP injection 
Statistical methods: 
A fully detailed Statistical Analysis Plan will be prepared before the database lock. 
Primary efficacy variable 
Overall proportion of patients, in each of the two dosage level group, not requiring additional 
anaesthesia for the duration of the surgical procedure will be presented together with 95% CI. 
 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
11 
 
Secondary efficacy variables 
Given the exploratory nature of the study, statistical evaluations will be mainly descriptive. 
Quantitative secondary endpoints will be summarized by means of descriptive statistics, as total 
number of evaluated subjects, mean, standard deviation, 95% confidence interval, median, minimum 
and maximum and number of missing values. 
Categorical measures will be reported as frequency, percentages of observed values and 95% 
confidence interval. 
Safety variables 
Quantitative safety endpoints will be summarized by means of descriptive statistics as total number of 
evaluated subjects, mean, standard deviation, median, minimum and maximum and number of 
missing values. 
Categorical safety endpoints will be reported as frequency and percentages of observed values. 
Adverse Events and Serious Adverse Events (AEs/SAEs) will be represented by frequency and 
percentage of patients with AE/SAE; AEs/SAEs will be summarized by the MedDRA System Organ 
Class (SOC) and Low Level Term (LLT), when calculating the number of AEs/SAEs within each 
SOC and LLT, each subject will only be counted once. 
Sample size estimate: 
The size of this study is based on the A’Hern method for single stage phase II designs.We estimate as 
satisfactory a success rate of around 90% (p1=90%) or more, while a success rate of 80% (p0=80%) or 
less will be considered inadequate; following the A’Hern formula based on the exact binomial 
distribution and assuming an 80% power and alpha=0.05, the required sample size, for each group, is 
82, with 72 being the minimum required number of successes to observe in order to  reach a conclusion 
in favour of the treatment’s efficacy. 
Expected drop out rate for the primary endpoint is low given that a single dose injection is requested, 
and assuming a 5% drop out rate 87 patients in each study arm shall be enrolled. In total 174 patients 
will be enrolled.  
Success rates and 95% CI will be presented separately for the two treatment groups, while a direct 
comparison will not be the focus of this study. 
FPFV: September 2018 
LPI: September 2020 
LPO: October 2020 
 
 
 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
12 
 
1.1 
Study Flow Chart 
 
Visits (Day) 
V1/Screening 
(-3 Weeks to Day 0) 
V2 (Day 1) 
Surgery/Discharge 
FU phone call 1
 (24 hrs ) 
FU phone call 2 
(7 Days-1/+2 days) 
Informed Consent Signature 
X 
 
 
 
Medical History 
X 
 
 
 
Physical Examination 
X 
 
 
 
Demography (sex, weight, 
height, BMI) 
X 
 
 
 
Vital signs(1) (blood pressure, 
heart rate) 
X 
X 
 
 
ECG(1) 
X (2) 
X 
 
 
Pregnancy test (3) 
X 
X 
 
 
Previous and Concomitant 
Treatments 
X 
X 
X 
X 
Inclusion/Exclusion Criteria 
X 
 
 
 
Enrolment 
X 
 
 
 
Randomization 
 
X 
 
 
Surgery 
 
X 
 
 
IMPs administration 
 
X 
 
 
Sensory block assessment 
(pin-prick test)(4) 
 
X 
 
 
Motor block assessment 
(Standard Bromage scale  (5) 
 
X 
 
 
Post-surgery pain intensity 
by FLACC scale(6) 
 
X 
 
 
Post-surgery pain intensity 
by Wong- Baker scale(7) 
 
X 
 
 
Post-surgery pain intensity 
by COMFORT scale(11) 
 
X 
 
 
Rescue medication during 
surgery 
 
X (8) 
 
 
 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
13 
 
Patient/Caregiver diary 
dispensation 
 
X 
 
 
Follow up questionnaire  
 
 
X 
X 
Rescue medication end of 
surgery 
 
X 
 
 
Rescue medication after 
home discharge 
 
 
X (9) 
X (9) 
Home discharge 
 
X 
 
 
Adverse Events(10) 
 
X 
X 
X 
 
1) Mandatory onlyfor infants aged 0-6 months at baseline visit, during the block until the end of the 
anaesthesia.  
2) ECG at screening visit is discretionary and it will be performed in infants aged 0-6 months only if 
foreseen by the routine hospital procedures. 
3) A urine pregnancy test will be performed only in fertile females. Kits will be provided by the 
Sponsor 
4) Performed in case of Inguinal hernia repair and 'Calcaneo stop' surgery 
5) Performed only in case of 'Calcaneo stop' surgery. 
6) Only for patients aged from 0 to < 6 years. 
7) Only for patients >6 years of age. 
8) Fentanyladministration when readiness for surgery not reached. 
9) Paracetamol intake after home discharge, recorded in parent’s diary. 
10) Severe neurotoxic or cardio-toxic events, caused by incorrect procedure leading to intravenous 
injection, will appear few minutes after Chloroprocaine administration and will be collected as SAE. 
11) Only for patients <2 months of age 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
14 
 
2. INTRODUCTION 
 
2.1 
Background information 
 
2.1.1 
Premise 
 
The present protocol is part of an extensive Pediatric Investigational Plan (PIP) which has been submitted to 
the Paediatric Committee (PDCO) of the European Medicine Agency (EMA) in the contest of the marketing 
authorization application of chloroprocaine use for perineural block. Following a comprehensive 
examination of the overall plan and the adoption of some adjustments suggested throughout the discussion, 
the PDCO has adopted a positive opinion on both the PIP and the present clinical protocol. 
 
2.1.2 
Local anaesthesia and PNB 
 
Regional analgesia, and specifically PNB, is an acceptable means of providing intraoperative anesthesia and 
postoperative analgesia in neonates, infants, and children while decreasing the use of systemic opioids and 
avoiding opioid-related adverse effects (1). With the advent of ultrasound and improvements in equipment in 
the last decade, the utilization of PNB in children has increased tremendously (2). 
Moreover, regional anesthesia including PNB has been shown to have several potential beneficial effects in 
this population including earlier tracheal extubation, effective blunting of the surgical stress response, and 
limiting the need for parenteral opioids. The addition of regional anesthesia to general anesthesia can also be 
used to improve intraoperative conditions by providing muscle relaxation without the need for 
neuromuscular blockers (3). 
The limitation of the requirements for volatile and other anesthetic agents may be desirable, given concerns 
regarding the potential impact of these agents on neurocognitive outcome in neonates and infants.  
PNB should routinely perform in awake adults, because general anesthesia or heavy sedation removes all 
opportunity to communicate symptoms of potential nerve injury.On the other side, infants and children may 
be unable to communicate symptoms of potential peripheral nerve injury and uncontrolled movement may 
increase the risk of injury. Therefore, the placement of PNBs in children undergoing general anesthesia or 
heavy sedation may be appropriate (4). 
For these reasons, actually, in contrast to adult practice, the majority of regional anaesthesia in children 
and infants is now performed under either deep sedation or general anaesthesia. Prospective and 
retrospective safety studies support the notion that performing regional anaesthesia under general 
anaesthesia is safe practice (5). Evidence-based literature shows that combined regional and general 
anaesthesia can decrease hospital stay and improve outcomes in paediatric patients (5). 
 
2.1.3 
Chloroprocaine 
 
Chloroprocaine hydrochloride (Chloroprocaine HCl [benzoic acid, 4-amino-2-chloro-2-(diethylamino) ethyl 
ester, monohydrochloride]) is a short-acting local anaesthetic belonging to the amino-ester class, 
characterized by a rapid onset of action (usually 6 to 12 minutes) and anaesthesia duration up to 60 min, 
depending on the amount used and the route of administration. In-vitro chloroprocaine half-life is 
approximately 21-25 seconds.  
In Switzerland (where the Applicant Sintetica S.A. is located), chloroprocaine hydrochloride has been 
authorized for epidural anesthesia and peripheral blocks since 1990 (Nesacaine® 1-2-3% injection, 
AstraZeneca). Of note, in 2007 the AstraZeneca reference drug product was withdrawn from the Swiss 
market. The action was undertaken for production technical reasons only, as reported by the Company, and 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
15 
 
not for safety reasons. This is also stated in the Swissmedic Journal where withdrawal of the product was 
classified as a ‘Marketing Authorization revocation following the decision of the company to forgo 
distribution’ (Swissmedic Journal, July 2007). 
Various formulations of preservative and antioxidant-free chloroprocaine HCl injectable solution for local 
anesthesia have been registered by the applicant in several countries. In particular, Sintetica S.A. is the 
Marketing Authorization Holder in Switzerland of chloroprocaine HCl 0.5% and 1% solutions for injection. 
This product, Ivracain® Sintetica (Chloroprocaine Hydrochloride 0.5%, Swissmedic registration n. 53,283), 
has been authorized and marketed since 1994 for intravenous regional anesthesia (IVRA) during upper and 
lower limbs surgery.  
Sintetica S.A. is the Marketing Authorization Holder in Switzerland of chloroprocaine Hydrochloride (HCl) 
0.5% and 1% solutions for injection. This product, Ivracain Sintetica (Chloroprocaine Hydrochloride 0.5%), 
has been authorized and marketed since 1994 for intravenous regional anesthesia (IVRA) during upper and 
lower limbs surgery. 
Chloroprocaine Hydrochloride 1% Sintetica has been on the Swiss market since 2002 for local anesthesia 
and PNBs. This formulation was locally distributed according to Swiss law “Formula Hospitalis” beginning 
in 2002 and was subsequently registered as medicinal product in 2008. Chloroprocaine Hydrochloride 1% 
Sintetica has also been imported by various hospitals in Belgium. 
In Europe, on March 19, 2012, following decentralized procedure, Marketing Authorization was obtained 
from the German Authority for Sintetica’s Chloroprocaine hydrochloride (Ampres) 1% for intrathecal 
administration. The product was assigned the status of New Active Substance. This marketing authorization 
was based on published literature plus non-clinical and clinical trials sponsored by the applicant Sintetica 
S.A. 
Currently, Chloroprocaine HCl 1% for intrathecal administration (under the brand names of 
Ampres/Clorotekal/Decelex) is registered in 9 European countries (Germany, Austria, France, Belgium, 
Spain, UK, Ireland, Poland and Italy). Via the registration process in Europe, Ampres 1% is currently 
licensed for intrathecal (spinal) anesthesia in adults where the planned surgical procedure is not expected 
to exceed 40 minutes. 
In July 2015, the applicant obtained Marketing Authorization approval in Switzerland for chloroprocaine 
HCl 10 mg/mL, 20 mg/mL and 30 mg/mL solutions for injection, for local anesthesia by infiltration, for 
PNB and epidural block, respectively, under the brand name Ampres 1, 2 and 3%. 
Whereas Chloroprocaine HCl 2% solutions are presently on the market in USA, Canada and Switzerland 
for the production of local anaesthesia by PNB and other administration routes, in Europe this local 
anaesthetic is not presently marketed as a 2% solution for the PNB indication, neither in adults nor in 
pediatrics. 
2.1.4 
Safety of local anaesthetics 
 
The mechanism of action of 2-chloroprocaine is the same of LAs that produce reversible loss of sensation, 
when applied to nervous tissue. Their primary site of action is the cell membrane and they produce their 
effect interacting directly with voltage-gated Na+ channels. It is now generally accepted that the 
mechanism of action of these compounds is based on the interaction with specific binding sites within the 
Na+ channels resulting in a blockade of the Na+ current. In higher concentrations, the other ion channels 
(K+, Ca++) might be affected as well (6). 
The most important clinical properties of LA agents are potency, onset, duration of action and blockade of 
sensory and motor fibres. These qualities are primarily dependent by physico-chemical properties of the 
compounds. The chemical structure of LA agents consists in 3 parts that affect the PK and 
pharmacodynamic properties: a lipophilic part, a hydrophilic part, and a chain that links the two parts. 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
16 
 
LAs can be divided in two groups according to the chemical link between lipophilic and hydrophilic parts: 
amide type drugs metabolized by hepatic microsomal enzymes, and ester type drugs, like 2-
chloroprocaine, hydrolyzed readily by plasma esterases. The potency and the duration of action of the 
anesthetics depend mainly on lipid solubility protein-binding and pKa (7). 
Local anesthetic toxicity is extremely rare in infants and children; specifically, if appropriately 
administered, in terms of dosage and anatomical location, PNB are relatively free of adverse effects. 
Relative contraindications include local infection, generalized sepsis, coagulopathy. Local anaesthetic 
systemic toxicity (LAST) ranges from mild systemic symptoms (auditory changes, circumoral numbness, 
metallic taste and agitation), to central nervous system findings (seizure, coma, respiratory arrest) and 
cardiovascular events (hypertension, hypotension, tachycardia, bradycardia, ventricular arrhythmias, 
cardiac arrest) (8). Peripheral nerve injury is an infrequent complication of regional anaesthesia. Because 
neurological injuries after PNBs are so rare, it is extremely difficult to obtain reliable and consistent data 
about their incidence. Most injuries are transient and often subclinical, or present as mild 
mononeuropathies. Allergic reactions with local anaesthetics are rare but could occur in patients 
hypersensitive to ester groups and could consist of pruritus, urticaria, edema and tachycardia. Central 
nervous system and cardiovascular system adverse reactions are generally dose-related and occur only 
with high plasma concentrations of local anaesthetics. These reactions are not expected with the indication 
of the present clinical protocol. 
 
2.1.5 
Chloroprocaine use in pediatric population 
 
To date there are limited data regarding the use of chloroprocaine in the pediatric patient. Interest in the use 
of 2-chloroprocaine for regional anesthesia in infants began in the early 1990s. At this time, regional 
anesthesia alternatives to general anesthesia were being sought to avoid postoperative apnea in preterm 
infants. The most common use of spinal anesthesia in the pediatric population is for preterm infant at risk for 
postoperative apnoea following general anesthesia. Spinal anesthesia is easiest to perform in infants 
weighing less than 3 kg, and is most practical when the duration of the surgical procedure is less than 90 
minutes. 
Although spinal anesthesia and single shot caudal epidural anesthesia were effective, the duration of surgical 
anesthesia with such techniques was limited, thereby eliminating the potential for more prolonged surgical 
procedures.  
Because of its extremely short duration of action, chloroprocaine has been used primarily for continuous 
epidural techniques in infants and children (3; 9; 10) and for femoral and lateral cutaneous nerve block in 
older children having muscle biopsy (11). Measured blood chloroprocaine concentrations in a very limited 
number of infants have been either zero or extremely low (9). None of the patients required supplemental 
analgesia, none required conversion to general anesthesia, and there were no reported complications. 
In adolescent, spinal anesthesia may be offered as an alternative to general anesthesia for low abdominal and 
lower-extremity procedures. 
Continuous caudal epidural infusion of 3% 2-chloroprocaine was utilized as an adjunct to general anesthesia 
(3; 12) limiting intraoperative opioid and volatile agent requirements allowing for earlier postoperative 
tracheal extubation. 
There are no reports of either sustained neurologic deficits or back pain after the use of chloroprocaine in 
pediatrics; however, most patients are infants or children with no, or limited, ability to communicate (13). 
 
 
 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
17 
 
2.1.6 
Ultrasound-guided PNB in children 
 
Several clinical studies show that PNBs can be performed in neonates and children to provide analgesia 
for several different surgeries (14; 15; 16; 17; 18; 19). Lidocaine, mepivacaine, bupivacaine, ropivacaine 
and, more recently, levobupivacaine are used worldwide for peripheral nerve blocks (20), as well as 
chloroprocaine (in US, Canada and Switzerland). Recently, the advancement in ultrasound technology has 
facilitated the placement of nerve blocks in children of all ages. Importantly, dosing has been decreased to 
a great extent, and accurate localization has provided more efficacious blocks. In addition, vascular 
structures are avoided. The main advantages conferred by ultrasonographically-guided techniques in 
children are the imaging of all anatomical structures and the possibility of directly ascertaining the 
position of the tip of the cannula relative to the nerve (21). Consequently, damage to important structures 
like nerves and vessels, during the injections, can be avoided and the risk of accidental nerve damage can 
be reduced, although care should be continually exercised using standard safety precautions to minimize 
any possible risk associated with the technique. Additional advantages lie with the faster onset of sensory 
and motor blocks, longer duration of blocks and increased block quality and success rate (22). In children, 
ultrasound-guided block dramatically reduces the volume of local anaesthetic required.The use of new 
technologies, such as ultrasound-guided regional anesthesia, that has shown several advantages in both the 
efficacy and safety profile of LAs, combined to the use of chloroprocaine, nowadays the safest LA, may 
represent the best choice in regional anesthesia in pediatrics. 
2.2 
Study rationale 
 
In children, nerve fibres are thinner, they have less myelin and the nodes of Ranvier stay closer to each 
other. Consequently, a regional block in children may spread further than the provider intends. 
Additionally, because the local anesthetic spreads easily in children, the duration of the block may be 
shortened compared to an adult. In general, as the patient’s age increases, local anesthetic latency of onset 
and duration of action increases as well. 
The LA should be tailored to the duration of the surgical procedure and the anticipated degree of pain. 
Therefore, selection of a short-acting agent such as chloroprocaine provides excellent intraoperative 
conditions, without the burden of an insensate limb for 10 to 18 hours postoperatively. For a greater 
degree of postoperative pain, the selection of a long-acting LA (e.g., ropivacaine) is more appropriate. 
Onset and duration for a given LA varies according to the nerve or plexus blocked. For example, at the 
brachial plexus, 0.5% ropivacaine may be expected to provide 10 to 12 hours of analgesia; the same 
concentration at the sciatic nerve may provide up to 24 hours of analgesia. This is likely due to differences 
in the local vascularity, which influences the uptake of LA. 
Of note, blocks for postoperative analgesia (often in concert with general anesthesia) do not require a high 
concentration of LA. Pediatric ambulatory patients who are undergoing short procedures with minimal 
postoperative pain (most ambulatory procedures) only require a short- to intermediate-acting agent. Short 
acting local anesthetic agents such as chloroprocaine may result the anesthetic of choice given its rapid 
onset, good intra-surgery control, very low toxicity profile, fast recovery offering the advantage of early 
home discharge. 
Calcaneo stop and inguinal hernia repair have been proposed as model surgeries to assess chloroprocaine 
efficacy and safety in pediatric patients in consideration that: 
 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
18 
 
− They are two types of ambulatory surgeries very commonly performed in pediatric hospitals. 
− They are highly representative for the clinical practice followed in European sites. 
− The proposed surgeries are highly reproducible from a procedural point of view among different 
centres. 
− They are considered ideal surgeries to test the efficacy properties of an anesthetic such as 
chloroprocaine. Indeed, they are both minor outpatient surgeries, where a very rapid onset of 
sensor and motor block is desirable to allow the management of pain limited to intra-operatory 
period. The management of post operatory pain can be achieved by the use of mild analgesics such 
as paracetamol and ibuprofen. 
− They are two outpatient surgeries that do not require the burden of sensor and motor block for 
several hours postoperatively. 
 
Importantly, short procedures with minimal postoperative pain (ambulatory procedures such as calcaneo 
stop and inguinal hernia repair) that only require a short- to intermediate-acting agent are considered the 
ideal surgeries for testing the clinical efficacy and safety of short acting local anesthetic agents such as 
chloroprocaine.  
The proposed operations may thus faithfully represent two of the more diffused medical conditions that 
need to be treated by mean of outpatient surgeries in the pediatric population; these two ambulatory 
surgeries can therefore considered representative to the product’s future clinical use of the product. 
Moreover, the inclusion of both the surgeries in the planned pediatric study permits a coverage of all the 
pediatric subsets (from preterm/neonates to adolescents).  
2.3 
Risks and benefits 
2.3.1 
Risks 
 
Potential risks of PNBinclude vascular puncture and bleeding, nerve damage and local anesthetic sistemic 
toxicity (LAST).  Despite these potential dangers, clinical evidence shows that PNB procedures are very well 
tolerated if appropriately administered in terms of dosage and anatomical location. 
2.3.2 
Benefits 
 
Clinical evidence demonstrates the benefits of PNB in terms of clinical outcomes. In particular, the adoption 
of PNB techniques has been associated with improvements in postoperative pain control and reduction in the 
use of opioids(which in turn minimizes the risk of adverse events), Thanks to the recent advances in 
ultrasound technology,an optimal needle placement can be achieved with very low dosage of anesthestic, 
which makes PNB an optimal option for children.  
 
Given the abovementioned considerations,as well as the ascertained safety of chloroprocaine, the risk-benefit 
profile for the conduct of this study appears to be favorable, thus making the investigational product an 
optimal candidate to be tested as a PNB agent in pediatric population undergoing ambulatory, short-term 
surgeries.  
 
According to clinical experience, recruitment rate of the study could be very critical due to the lower 
incidence of day-case short duration surgical procedures in pediatric population as compared to adults. For 
this reason a six months rate check will be performed. In case recruitment rate is found to be lower than 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
19 
 
expected (i.e. two patients/month), a protocol amendment will be submitted to include additional clinical 
centres in the study and to ask for a further delay of the study. 
3. STUDY OBJECTIVES 
 
The general objective of the study is to evaluate, in pediatric population undergoing 'calcaneo stop' surgery 
or inguinal hernia repair, the efficacy and safety of chloroprocaine 1% and 2% for peripheral nerve block 
based on concentration–response relationships. 
3.1       Primary Objective 
 
The primary objective of the study is the assessment of the efficacy of perineural injection of 
chloroprocaine 1% and 2% in pediatric population for a successful peripheral nerve block (same volume 
ml/Kg) in terms of proportions of subjects not requiring rescue anesthesia during surgery. 
In the context of the present clinical protocol, a peripheral nerve block is defined as successful if the 
induced anaesthesia is adequate for the surgery (complete sensory block) without any supplementation in 
the first 45 min (even if surgery lasts for > 45 min), calculated from the time of readiness for surgery 
(complete sensory block). 
3.2       Secondary Objectives 
 
Efficacy: 
 
The secondary, efficacy objectives of the trial will be evaluated on the two dosage level groups separately, 
on the two surgical procedures, considering both dosage levels, and will consist in the assessment of the 
following parameters: 
 
• 
time to onset of sensory block starting from completion of the IMPs injection (corresponding to 
readiness for surgery), detected by pin-prick testin case of Inguinal hernia repair 
(ileogastric/ileoinguinal nerve block).The response to pinprick in sedated patient will be associated 
to at least a 20% increase from baseline in heart rate (HR). The sensory block onset will be achieved 
if no apparent hemodynamic reaction to pinprick will be seen (defined as an increase in heart rate in 
excess of 20% compared with baseline levels), meaning that the patient is ready for surgery. 
• 
time to onset of sensory block starting from completion of the IMPs injection (corresponding to 
readiness for surgery), detected by pin-prick test in case of ‘calcaneo stop’ (sciatic nerve block). The 
measurement of the heart rate will serve as confirmatory test as for inguinal hernia repair surgery. 
• 
time to regression of motor block (sciatic nerve block) by standard Bromage scale, at the start of 
patient’s awakening,in case of calcaneo stop procedure. The assessment will be repeated 30 minutes, 
1 hour, 2 hours and 3 hours after the first evaluation This phase will have to be monitored with 
particular care since events of agitation followed by numbness are very common in children after 
sevoflurane anesthesia. 
• 
pain intensity, assessed five times in the first 3 hours after the end of surgery and during the home 
discharge visit (V2). Post-surgery assessment will be performed immediately at awakening and 30 
minutes, 1 hour, 2 hours and 3 hours after this first evaluation. The following tools will be used for 
pain evaluation: COMFORT scale for patients <2 months of age, FLACC scale for patients aged  2 
months  6 years, and Wong-Baker scale for patients over 6 years of age, respectively; 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
20 
 
• 
time to eligibility for home discharge defined as: “the time elapsed from completion of surgery to the 
time when criteria for discharge are met, regardless if the patient will be discharged from the hospital 
at a later time, according to the hospital procedures”. The criteria for discharge will be defined 
according with the Pediatric Post Anesthesia Discharge Scoring System (Ped-PADSS). 
• 
if rescue anaesthesia (fentanyl) was required during both surgical procedures performed; 
• 
time and dosage of rescue anaesthesia (fentanyl) required during surgery, in addition to 
Investigational Medicinal Products (IMPs) injection; 
 
Safety: 
 
The secondary, safety objectives of the trial will be to assess: 
 
• 
the general tolerability and safety of the study drug, assessed through summaries of adverse events; 
 
• 
Pain at injection site, neurological symptoms (such as: convulsions) and cardiac symptoms (such as 
bradycardia and heart failure etc.) evaluated during surgery after IMP injection. 
4. STUDY DESIGN 
4.1 
Study overview and plan 
 
This is a prospective, randomized, multicenter, double blind, parallel active groups, concentration-response 
model, phase II clinical trial, aimed at evaluating the efficacy and safety of chloroprocaine 1% and 2% for 
peripheral nerve block in pediatric population undergoing 'calcaneo stop' surgery or inguinal hernia repair, 
based on concentration–response relationships. ‘Calcaneo stop’ and inguinal hernia repair have been chosen 
as testing surgeries based on the following considerations: 
 
− 
Calcaneo stop surgery is a common, simple, reliable, and minimally invasive procedure for the 
treatment of pediatric flexible flatfoot performed on children from 6 years to adolescence. Sciatic nerve 
block offers minimal postoperative pain control after calcaneo stop surgery in children (23) and 
effective analgesia is achieved by use of paracetamol. Flexible flatfoot is the most prevalent condition 
seen in pediatric orthopaedic clinics; according to the published data, the incidence is about 5% in 
children and adults (24). The mean surgery duration is about 15-30 minutes. 
 
− Inguinal hernia repair is globally the most frequently performed surgical procedures in children (25). At 
the end of operation, most children only need paracetamol or ibuprofen by mouth every four to six 
hours for the first 24 hours after surgery. The overall incidence of inguinal hernias in childhood ranges 
from 0.8% to 4.4%. One third of all children with hernias present before six months of age and 
outpatient surgeries may be routinely performed on children till 6 years of age. The incidence is much 
higher in premature infants; inguinal hernias develop in 13% of infants born before 32 weeks gestation 
and in 30% of infants weighing less than 1000 g (25). Importantly, many surgeons repair inguinal 
hernias before discharge from the neonatal intensive care until once the infants reach 1800 to 2000g 
(26), with babies that on some occasions are less than 2 months. The mean surgery duration is about 30-
45 minutes. 
 
The study consists of a treatment period of 1 day and of a single perineural injection, administered through 
ultrasound-guided technique in order to avoid the risk of chloroprocaine IV injection. 
 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
21 
 
The Principal Investigator’s site will be located Italy, the other involved study sites are indicatedin the Site 
List provided separately from the present document.The number of patients to be included is 174 (87 per 
treatment group, allocated to 1% or 2% arm in a ratio of 1:1 according to the randomization list). Details 
about the randomization procedure are reported in section 6. 
 
Two IMPs will be used during the trial, namely Chloroprocaine Hydrochloride (benzoic acid, 4-amino-2-
chloro-2-(diethylamino) ethyl ester, monohydrochloride) aqueous solutions for injection,at a concentration of 
1% and 2%, respectively 
 
IMPs will be injected after induction of general anaesthesia; onset of sensory block  induced by 
Chloroprocaine HClwill be assessed by pin-prick test associated with heart rate assessment (for both sciatic 
nerve or ilioinguinal/iliohypogastric nerve blocks) before surgery. 
 
The treatment periodlasts for 1 day and consists of a single, perineural, ultrasound-guided injection. 
 
Before surgery, patients will be administered a pre-IMP treatment according to the following pattern: 
- Midazolam,that will be administered orally, only in patients > 6 months of age, 45 min before 
surgery (according to local routine practice); and 
- Sevofluraneby inhalation will be given, as recommended by local routine practice, in order to induce 
general anaesthesia, after midazolam sedation and before IMP administration. Patients will breath 
unaided and, unless necessary as an emergency measure, they are not supposed to be intubated in the 
frame of this preoperative procedure.  
 
Immediately after the end of the surgical intervention, all patients will be administered Paracetamol 15 
mg/kg, byi.v. injection 
 
The study consists of 2 visits, and 2 telephone follow-up calls, in accordance with the following schedule: 
 
− 
Screening visit (V1); 
− 
Surgery and discharge visit (V2); 
− 
Follow Up safety phone call Day 1(24 hours post-surgery); 
− 
Follow Up safety phone call Day 7 (7 Days-1/+2 days post-surgery). 
5. STUDY POPULATION 
5.1 
Number of Patients 
 
The number of patients to be recruited is estimated to 174 patients undergoing 'Calcaneo stop' surgery or 
Inguinal hernia repair, and fulfilling the eligible criteria indicated below. Further details are reported in 
section 11.1 (Rationale for sample size calculation). 
5.2 
Inclusion Criteria 
 
1. Male and female paediatric patients from birth to <18 years scheduled for one of the following 
surgical procedures whose duration, according to clinical experience, should not exceed 45 minutes: 
- 'calcaneo stop' surgery  (6 to <18 years; children and adolescents) planned for sciatic nerve 
block short-lasting anaesthesia, 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
22 
 
- inguinal hernia repair (0 to 6 years; newborn infants, infants-toddlers and children) planned 
for ilioinguinal/iliohypogastric block  short-lasting anaesthesia; 
2. Normally active and otherwise judged to be in good health on the basis of medical history, physical 
examination, with normal body mass index (BMI18,5 – 24,9 Kg/m2 inclusive) and normal body 
development (normal weight and height according to local paediatric Height and Weight Chart); 
3. ASA I and ASA II patients 
4. Written informed consent provided by parents/tutor, willing and able to understand the purpose of 
the study, including possible risks and side effects, and willing and able to comply, on their behalf 
and of the minor, with the study requirements. 
5. Willing and able to give additional written informed consent by itself, in case of children and 
adolescents, in addition to parents/tutor. 
6. Willing and able, in case of children and adolescents, to comply with the study requirements on their 
behalf. 
5.3 
Exclusion Criteria 
 
1. ASA > II patients 
2. Preexistent infection at injection site; 
3. Use of opioids, antidepressants, anticonvulsant, sulfonamide, vasopressors,  ergot-type oxytocic 
drug and mixtures of local anaesthetics, antiarrhythmic drug class III, such as amiodarone, strong 
inhibitors of CYP1A2, such as fluvoxamine and enoxacin; 
4. Use of medication(s) known to interfere with the extent of regional blocks for 2 weeks before the 
start of the study; 
5. History of drug or alcohol abuse; 
6. Sensitivity among the study medication active ingredient, the members of the PABA esters group 
and amides-type local anesthetic group; 
7. Clinical history of allergy, hypersensitivity or intolerance to the study medication or other 
medications used during surgery; 
8. Pregnancy and lactation: positive pregnancy test at screening (if applicable), pregnant or lactating 
(The pregnancy test will be performed to all fertile subset)  
9. Participation in any other clinical study within the 3 months prior to the screening. 
6.CRITERIA AND PROCEDURE FOR RANDOMIZATION 
6.1 
Treatment allocation 
 
The study treatment will be administered to all the participants at Visit 2, before surgical intervention. All 
eligible patients will be allocated to the relevant treatment group through a randomization list which will be 
prepared in accordance with the following criteria: 
 
− The full study population (n = 174) will be equally distributed between the two treatment arms (87 
patients for chloroprocaine 1% and 87 patients for chloroprocaine 2%); 
 
− Within each treatment arm, 43 patients will undergo inguinal hernia repair surgery and 44 patients 
will undergo calcaneo stop surgery; 
 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
23 
 
− In order to ensure adequate representation of all age ranges, the minimum number of participants in 
each of the age subsets is expected as follows: 
 
a. Preterm and/or term newborn infants (0-27 days) n = 26 
b. Infants and toddlers (28 days to 23 months) n = 30 
c. Children 2-6 (2 to 6 years) n = 30 
d. Children 6-11 (6 to 11 years) n = 44 
e. Adolescents (12 to 18 years) n= 44 
6.2 
Blinding 
 
The present study will be conducted according to a Double-Blind model: none of the involved players 
(patient, caregiver, investigator, outcomes assessor) will thus be aware of the treatment allocation.Once 
eligibility is established, the treatment assignement will be performed via web, by means of an allocation 
system embedded in the e-CRF platform. All details about the procedure to be followed for the treatment 
assignment will be provided in the IMP Manual which will be supplied to the investigators prior to site 
activation. 
The original randomization list will be developed and kept by the designated CRO as well as by the Sponsor. 
Syringes for injection will be prepared in an area adjacent to the operating room by a person not involved in 
any other study activity. Right after preparation, the syringe will be given to the blinded anesthetist who will 
proceed with the administration by means of a line which will have to be long enough to keep the syringe out 
of the sterile area. The operator in charge of the study drug preparation will take care of completing the IMP 
sheet that will be present in each package.The completed sheet will be kept together with the other patient 
records under responsibility of the investigator. 
6.3 
Emergency unblinding 
 
The blinding of the trial will be maintained for the entire duration of the study until database lock, however, 
participants may be unblinded during the trial for the occurrence of a medical emergency.  To this aim, each 
IMP kit will be supplied together with the relevant sealed envelope to be used for code break in case of 
emergency. The envelopes will be brown-colored and will not have any window, in order to ensure that the 
contents cannot be seen when held up to the light. A detailed Standard Operating Procedure (SOP) to be 
followed to perform the code break will be provided to the investigators. If unblinding is required, the 
following information will have to be recorded by the involved site staff (Principal Investigator, Co-
investigator, Pharmacist): 
• 
Date and time of the code break 
• 
Reason for the unblinding 
• 
Actions taken 
• 
Details of the person(s) involved in the code break 
• 
Patient study number/trial identifier 
 
All code break envelopes must be collected by the PI and reconciled by the clinical monitor at the end of the 
study 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
24 
 
7.STUDY CONDUCT 
7.1 
Study Duration 
 
The study protocol foresees a screening visit (that could be performed from three weeks before the surgery), 
1 study treatment for each patient, followed by 2 telephone follow up calls (24 hours and 7 days after 
surgery). 
Themaximum study duration will be approximately 28 days, screening visit and follow-up included.A 
detailed list of the study assessments and related timeframes is reported in sections 7.2 (Detailed study plan) 
and 1.1 (Study Fow Chart). 
7.2 
Detailed StudyPlan 
7.2.1 
VISIT V1: Screening phase 
 
During the screening phase, fulfilment of eligibility criteria will be verified.The following tests and 
procedures will be performed: 
 
1. Informed Consent review and signature; 
2. Inclusion and exclusion criteria assessment; 
3. Medical history; 
4. Demography (sex, weight, height, BMI); 
5. Vital signs (blood pressure, heart rate); 
6. ECG (when relevant); 
7. Previous and concomitant treatments; 
8. Pregnancy test (when relevant); 
9. Enrolment; 
7.2.2 
VISIT V2: Surgery and Discharge (Day1) 
 
The screened patients will be considered eligible for randomizationonce the following conditions will be 
fulfilled: 
a. all procedures, tests and examination required during the screening visits have beencompleted; and 
b. all eligibility criteria for entry into study are met 
 
The following tests and procedures will be performed: 
 
1. Vital Signs (blood pressure and heart rate); 
2. ECG (when relevant); 
3. Pregnancy test (when relevant); 
4. Previous and concomitant treatments; 
5. Randomization; 
6. IMPs administration; 
7. Surgery 
8. Sensory block assessment (pin-prick test, before intervention, for both surgeries); 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
25 
 
9. Motor block assessment (Standard Bromage scale, after patient’s awakening, for ‘calcaneo stop’ 
surgery only); 
10. Assessment of post-surgery pain intensity by one of the following scales according to patient’s age:   
a. FLACC scale (for patients aged  2 months  6 years) 
b. Wong-Baker scale (for patients over 6 years of age) 
c. COMFORT scale (for patients <2 months of age); 
11. Rescue medication during surgery; 
12. Parent/Caregiver diary dispensation; 
13. Rescue medication end of surgery; 
14. Evaluation of eligibility for home discharge (Ped-PADSS); 
15. Recording of Adverse events;  
7.2.3 
TELEPHONE FOLLOW UP VISITS 
 
FU Day 1 (24 hrs post-surgery) 
 
The following tests and procedures will be performed: 
1. Recording of concomitant treatments; 
2. Follow up questionnaire; 
3. Recording of rescue medication after home discharge; 
4. Recording of Adverse Events; 
 
FU Day 7 (-1/+2 days post-surgery) 
The test and procedures described below will be performed: 
1. Recording of concomitant treatments; 
2. Follow up questionnaire  
3. Recording of rescue medication after home discharge; 
4. Recording of Adverse Events. 
8.TRIAL PROCEDURES AND ASSESSMENTS 
8.1 
Physical examination and vital signs 
 
A comprehensive physical examination inclusive of vital signs measurements at rest (height, weight, 
temperature, blood pressure, heart rate, respiratory rate and BMI) will be performed at the screening visit. 
Vital signs will be performed at baseline, during the block until the end of the anaesthesia.  
 
− Height: in children younger than two years, body length should be masured in the supine position. In 
older children, the height measurement should always be done with the patient standing. 
 
− Weight: it is recommended to use a scale with  the following features: 
o Solidly built and durable 
o Electronic (digital reading) 
o Measures up to 150 kg 
o Measures to a precision of 0.1 kg (100g) 
o Allows tared weighing 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
26 
 
 
Children younger than two years may be weighed through tared weighing while held by the parent or 
tutor. Whenever possible, it is recommended to weigh older children alone, in standing position.It is 
recommended to remove clothing before weighing, in order to obtain a more accurate measurement. 
 
− Temperature: rectal temperature recordings are preferred in infants and children younger than two 
years, axillary recordings are recommended for older patients. According to the local routine, both 
digital and mercury-glass thermometers can be used for the recording. 
 
− Blood Pressure: devices for the measurement of blood pressure may include the standard extremity 
cuff and mercury bulb sphygmomanometer, the hand-held aneroid manometer, and the doppler and 
oscillometric devices. Any of the abovementioned procedures can be acceptable in the frame of this 
study as long as the blood pressure is measured according to the local routine procedure. Regardless 
the adopted procedure, it is suggested that patients old enough to understand should be shown the 
blood pressure device before the examiner attempts to take a measurement. The patient should be 
allowed to play with the device or feel the cuff inflate to gain his or her cooperation.  
 
− Heart rate: The heart rate can be measured by direct auscultation or palpation of the heart or 
peripheral arteries (carotids, femorals, brachials, or radials). 
 
− Respiratory rate: The respiratory rate can be obtained by auscultation, palpation, or direct 
observation 
 
− BMI: Body Mass Index should be determined according to the following formula:  
 
Weight in kg ÷ squared length/height in metres 
 
It is very important to use a length measurement for a child less than 2 years old and a height 
measurement for a child age 2 years or older. If necessary, convert height to length (by adding 0.7 
cm) or length to height (by subtracting 0.7 cm) before determining the child’s BMI. 
A BMI Table and related reading procedure will be provided to the study investigators prior to study 
initiation. 
8.2 
Electrocardiogram 
 
An ECG,foreseen only for infants aged 0-6 months, will be performed at screening (only if foreseen by the 
routine hospital procedures) and baseline visits, respectively.  
The electrodes will have to be placed in theirusual positions, and any effort should be done in order to 
prevent the child from moving during the acquisition. 
8.3 
Sensory block assessment 
 
Sensory block is defined as absent thermal and sensitive perception in each nerve territory. In this study,  
sensory block will be evaluated using the pin-prick test technique. The stimulation will be done every 4 to 5 
minutes after IMP injection,by means of pliers on the area of intervention, with the patient asleep, right 
before the start of the surgery. The response to pinprick in sedated patient will be associated to at least a 20% 
increase from baseline in heart rate (HR). The sensory block onset will be achieved if no apparent 
hemodynamic reaction to pinprick will be seen (defined as an increase in heart rate in excess of 20% 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
27 
 
compared with baseline levels), meaning that the patient is ready for surgery.Once the sensory block has 
been achieved the investigator will start the surgery according to local routine practice. 
8.4 
Motor block assessment 
 
The time to regression of motor block, foreseen only for ‘calcaneo stop’ surgery, will be assessed by means 
of the standard Bromage scale (27). The evaluation will be performedimmediately at patient’s awakening 
and it will be repeated 30 minutes, 1 hour, 2 hours and 3 hours after the first evaluation. The awakening 
phase will have to be monitored with particular care since events of agitation followed by numbness are very 
common in children after sevoflurane anesthesia. 
In the standard Bromage scale, the intensity of motor block is assessed by the patient's ability to move 
his/her lower extremities. When using this scale for research in labour analgesia, it is important to measure 
motor block intermittently throughout labour, as the degree of block will change. It is also important to 
measure motor block in both legs, since the block may be asymmetrical. Although several modifications of 
the Bromage scale have been described, including the use of more gradations of motor block, in the present 
study we refer to the standard one, whose levels of measurement are described by the table below: 
 
 
 
 
 
 
 
8.5 
Post-surgery pain intensity 
 
Pain intensity will be evaluated for both surgeries at different timepoints: five times in the first 3 hours after 
patient’s awakening and during the home discharge visit (V2). Post-surgery assessment will be performed 
immediately after the awakening and it will be repeated 30 minutes, 1 hour, 2 hours and 3 hours after the 
first evaluation. The technique and appropriate scale for pain measurement are age-dependent therefore, 
different tools will have to be used for the evaluation: 
8.5.1 
COMFORT scale for patients aged < 2 months of age 
 
The COMFORT Scale (28) is a pain scale that may be used to assess pain when a person cannot describe or 
rate their pain. For this reason, some of the common populations this scale might be used with include: 
− children 
− cognitively impaired adults 
− adults whose cognition is temporarily impaired, by medication or illness 
− the learning disabled 
− sedated patients in an ICU or operating room setting 
 
The COMFORT Scale is based on the evaluation of 9 parameters (alertness, calmness, respiratory response, 
crying, movement, mean arterial blood pressure, heart rate, muscle tone and facial expression), all ranging 
between 1 and 5 (maximum distress indicated by 5 points).  Overall, it  provides a pain rating between 9 and 
45. 
 
Grade
Criteria
Degree of block 
I 
Free movement of legs and feet 
Nil (0%) 
II 
Just able to flex knees with free movement of feet 
Partial (33%) 
III 
Unable to flex knees, but with free movement of feet Almost complete (66%)
IV 
Unable to move legs or feet 
Complete (100%) 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
28 
 
8.5.2 
FLACC scale for patients aged    2 months  6 years 
 
The FLACC (29) is a behavioral scale that has been validated for assessment of postoperative pain in 
children between the ages of two months and seven years. The acronym “FLACC” represents five 
categories: face, legs, activity, cry and consolability. Responses in each category are scored between 0 and 2, 
foa a maximum total score of ten. To use the FLACC scale the clinician should observe a child for one to 
five minutes. A pain score is obtained by reviewing the descriptions of bahavior in each of the FLACC 
categories and selecting the number that most closely matches the observed behavior. The numbers obtained 
for each category are added together to obtain the total pain score, which will be between 0 and 10. It may be 
necessary to touch and reposition the child to determine if pain is present with movement and to better assess 
tension and rigidity in the body. 
8.5.3 
Wong-Baker scale for patients over 6 years of age 
 
The Wong Baker Faces Pain Scale (30) combines pictures and numbers to allow pain to be rated by the 
user. It can be used in children over the age of 3, and in adults. The faces range from a smiling face to a sad, 
crying face while the numerical rating assigned to each face is arranged in six levels, 0-2-4-6-8 and 10 
respectively, with the ‘zero’ (smiling face) corresponding to the absence of pain and the ‘10’ (crying face) 
corresponding to an extreme hurt.  
8.5.4 
Pediatric Post Anesthesia Discharge Scoring System (Ped-PADSS) 
 
The Ped-PADSS (31, 32) is a  a pediatric adaptation of the postanesthetic discharge scoring system 
(PADSS), a gold standard to assess home readiness after ambulatory surgery in adults (33, 34). Ped-PADSS 
was built using validated criteria extracted from Chung’s PADSS. The ﬁve items - hemodynamic status, 
level of consciousness, pain, nausea and vomiting, and bleeding of the surgical site -  are recorded on a scale 
from 0 to 2. A Ped-PADSS score 9 at 1-h intervals is needed to allow discharge from the hospital with the 
following three additional conditions required: absence of any breathing difﬁculty or hoarse voice; no 
request from parents to see the anesthetist before discharge; no requirement wish of the anesthetist to see 
parents or child before discharge. 
8.6 
Post-discharge assessments 
 
The post-operative progress, mainly as to what concerns patients’ safety and well-being,will be monitored 
until 7 days after discharge. In particular, the following information will be collected: pain at the injection 
site, pain at the site of surgery, occurance of expected/unexpected adverse events, concomitant medications. 
Post-operative progress after discharge will be monitored by means of the following tools:  
 
a) the Investigator or his deputy will contact the patients by telephone and will question them about any 
adverse reactions which might have occurred after discharge. Neurological and other symptoms will 
be assessed through an interview using a specific questionnaire, that will be performed twice (24 
hours and 7 days after surgery, respectively) 
b) weekly diary, to be completed (by the patient or caregiver depending on participant’s age) every day 
during the first week after discharge. A copy of the completed diary will have to be returned to the 
site via email, fax or courier, as agreed with the investigator at the time of diary dispensation. 
 
A sample copy of both the questionnaire and the diary is provided in Appendixes 17.5 and 17.6, respectively. 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
29 
 
9.STUDY DRUG 
9.1 
Study Drugs Description 
 
Two IMPs will be used during the clinical study - Chloroprocaine HCl (benzoic acid, 4-amino-2-chloro-2-
(diethylamino) ethyl ester, monohydrochloride) aqueous solutions for injection in two different 
concentrations, i.e.: 
 
− Chloroprocaine Hydrochloride 1%: (10 mg/mL); injectable solution, Sintetica S.A., Switzerland, 5 
ml ampoules 
− Chloroprocaine Hydrochloride 2%: (20 mg/mL); injectable solution, Sintetica S.A., Switzerland, 20 
ml vials 
 
IMPs shelf-life: Chloroprocaine HCl1% and 2% are commercially available and authorized with a shelf-life 
of 30 months and 36 months respectively. 
 
IMPs storage conditions: Chloroprocaine HCl1% and 2% must be stored protected from light, in sealed 
original packaging and at room temperature ( 15-25° C ). 
 
Further details about study drug preparation and handling are reported in the IMP Manual provided to the 
investigators.  
9.2 
Dosage and administration 
 
Doses to be used during the study: 
- 
Sciatic nerve block for  'Calcaneo stop' surgery: 0,5 ml/kg for both IMPs (Chloroprocaine HCl1% 
and Chloroprocaine HCl2%); 
- 
Ilioinguinal/iliohypogastric nerve block for inguinal hernia repair: 0,3 ml/kg for both IMPs 
(Chloroprocaine HCl1% and Chloroprocaine HCl2%). 
 
IMPs will be injected after induction of general anaesthesia; onset of sensory block induced by 
Chloroprocaine HCl will be assessed by pin-prick test for both sciatic nerve or ilioinguinal/iliohypogastric 
blocks. 
- The investigational medicinal products will be administered by ultrasound-guided perineural 
injection,to be performed very slowly, with repeated aspirations, with the patient asleep for the 
effects of the general anesthesia and positioned supine. The needle (whose length will be calibrated 
on the basis of the type of surgery as well as of other relevant parameters such as patient’s age and 
anthropometric measurements) will be inserted via a lateral approach, in-plane with the transducer 
and perpendicular to the ultrasound beam in order to optimize needle visualization. The ultrasound 
transducer will work at high frequency. 
 
Site of Injection: Sciatic nerve (mid-thigh region) for  'Calcaneo stop' surgery or ilioinguinal/iliohypogastric 
nerve (along anterior superior iliac spine (ASIS) and navel)for inguinal hernia repair. 
 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
30 
 
9.3 
Packaging and Labeling 
 
Packaging and labeling of the IMP will be carried out by the Sponsor according to the randomization list and 
to European GMP Annex 13, February 2010 revision.Labeling in local language will be applied in such a 
way that it should not obscure the original label. The labels will be provided with a tear-off portion to be 
attached to the appropriate investigational product administration form. All related instructions for the 
investigator will be provided in the IMP Manual. 
9.4 
Accountability And Compliance 
 
It is the investigator/institution’s responsibility to make all reasonable efforts to assure that:  
 
- 
Trial-specific product delivered to the site are correctly received (the CRO clinical trial monitor will 
collect the signed and dated receipt form); 
- 
study medication is handled in a safely and properly manner and it is stored in a secured area; 
- 
study medication is administered to participants in accordance with the protocol requirements 
 
IMP will be administered to subjects only by authorized personnel (Principal Investigator, Co-Investigators 
and nurses under the Principal Investigator direct responsibility). 
Drug inventory and accountability records will be kept by the Investigator or by the Pharmacist, or other 
authorized person. 
To ensure adequate records, all study medication will be accounted for in the case report form and drug 
accountability inventory forms. The inventory will include details of the received and used study medication. 
At the end of the study, used, unused and partially used supplies of test and reference investigational 
products provided by the sponsor/manufacturer will either be destroyed on site (upon written authorisation) 
or returned to the sponsor/manufacturer, after assessment of drug accountability. 
This being an IMP intended to be used only once, as a pre-surgical treatment and therefore destined to be 
administered only by study staff at clinical site, no compliance issues are foreseen.  
In order to allow traceability of the performed operations, before administration the investigator will have to 
record on the e-CRF the relevant IMP code and batch number, as well as the date and time of administration.  
9.5 
IMP dispensing to patients 
 
This being an IMP intended to be used only once, as a pre-surgical treatment and therefore destined to be 
administered only by study staff at clinical site, no dispensing to patients is foreseen.  
9.6 
Other drugs to be used in the study 
 
9.6.1. 
Premedication before surgery 
 
Patients will be pre-treated with: 
- 
Midazolam: will be given for oral administration, only in patients > 6 months of age, 45 min 
before surgery according to local routine practice. 
- 
Sevoflurane by inhalationwill be given,as recommended by local routine practice,in order to 
induce general anaesthesia,after midazolam sedation and before IMP administration. Patients 
will breath unaided and, unless necessary as an emergency measure, they are not supposed to be 
intubated in the frame of this preoperative procedure.  
 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
31 
 
9.6.2. 
Rescue anesthesia during surgery 
 
Sensory block will be assessed by pin-prick test after chloroprocaine injection.  In case of incomplete 
sensory block (when readiness for surgery not reached), fentanyl by IV injection will be given, at the dosage 
indicated by local routine practice, as rescue anaesthesia. All details about the administration of the rescue 
anesthesia will have to be recorded on the relevant CRF.  
 
9.6.3. 
Rescue analgesic treatment 
 
Paracetamol, oral or suppository, is allowed for rescue analgesic treatment after home discharge 
9.7 
Concomitant medications 
9.7.1. 
Allowed medications 
 
Any medications (other than those excluded by the clinical protocol in the section 9.7.2 below) that are 
considered necessary for the patients’ welfare and will not interfere with the trial medication may be 
prescribed during the study at the Investigator’s discretion. 
The Investigator will record all concomitant medications taken by the subject during the trial, from the date 
of signature of informed consent, in the appropriate section of the eCRF. 
Any additional concomitant therapy that becomes necessary during the trial and any change to concomitant 
drugs must be recorded in the corresponding section of the eCRF, noting the name, dose, duration and 
indication of each drug. 
Hormonal contraceptives for females of childbearing potential are permitted. 
 
9.7.2. 
Not allowed medications 
 
The use of any of the medications listed below is not permitted during the study: 
 
− Vasopressors; 
− Ergot-type oxytocic ; 
− Sulphonamides;  
− Mixtures of local anaesthetics;  
− Opioids;  
− Antidepressants; 
− Anticonvulsants;  
− Antiarrhythmic drug class III, such as amiodarone; 
− Strong inhibitors of CYP1A2, such as fluvoxamine and enoxacin. 
10.SAFETY AND PHARMACOVIGILANCE 
 
A Comprehensive assessment of any apparent toxicity experienced by the participants will be performed 
throughout the course of the trial, from the time of the patient’s signature of informed consent to the end of 
the observational period at day 7 (-1/+2)/2nd telephone FU. Trial site personnel will report any adverse event 
(AE), whether observed by the Investigator or reported by the patient/caregiver. 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
32 
 
The safety profile of the Investigational Medicinal Product will be assessed through the recording, reporting 
and analyzing of baseline medical conditions, adverse events, physical examination findings including vital 
signs and ECG. 
Adverse events will be recorded after the subject has signed the study Informed Consent, at V2 and at the 
two telephone Follow Up calls.  
All relevant details are provided in the following sections 10.1 – 10.5. 
10.1 
Adverse Event definition 
 
An Adverse Event (AE) is any symptom, sign, illness or experience that develops or worsens inseverity 
during the course of the study. Intercurrent illnesses or injuries should be regarded asAdverse Events. 
Abnormal results of diagnostic procedures are considered to be Adverse Events ifthe abnormality: 
− results in study withdrawal; 
− is associated with a serious Adverse Event; 
− is associated with clinical signs or symptoms; 
− leads to additional treatment or to further diagnostic tests; 
− is considered by the investigator to be of clinical significance. 
10.2 
Serious Adverse Event 
 
Adverse Events are classified as serious or non-serious. A Serious Adverse Event is any AE that is: 
− fatal; 
− life-threatening; 
− requires or prolongs hospital stay; 
− results in persistent or significant disability or incapacity; 
− a congenital anomaly or birth defect. 
All Adverse Events that do not meet any of the criteria for serious should be regarded as nonseriousAdverse 
Events. 
10.3 
Adverse Event Reporting Period 
 
The study period during which Adverse Events must be reported is normally defined as the periodfrom the 
initiation of any study procedures to the end of the study treatment follow-up. 
The Investigator/coordinator must report all adverse experiences (AEs) that occur throughout the study 
according to the appropriate procedures listed below. If the Investigator becomes aware of any possible 
Serious Adverse Event (SAE), including death, he/she must report this event by phone and fax/email the 
SAE form to the study sponsor within 24 hours of notification of the event. 
10.4 
Recording of Adverse Events 
 
At each contact with the subject, the Investigator must seek information on Adverse Events byspecific 
questioning and, as appropriate, by examination. Information on all Adverse Events should be recorded 
immediately in the source document, and also in the appropriate Adverse Event moduleof the appropriate e-
CRF form. All clearly related signs, symptoms, and abnormal diagnosticprocedures results should recorded 
in the source document, though should be grouped under onediagnosis. 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
33 
 
All Adverse Events occurring during the study period must be recorded. The clinical course of eachevent 
should be followed until resolution, stabilization, or until it has been determined that the studytreatment or 
participation is not the cause. Serious Adverse Events that are still ongoing at the endof the study period 
must be followed up to determine the final outcome. Any Serious Adverse Eventthat occurs after the study 
period and is considered to be possibly related to the study treatment or study participation should be 
recorded and reported immediately. 
10.5 
Reporting of Serious Adverse Events 
 
The pharmacovigilance will be under the control of the Sponsor,Sintetica SA. Any Serious Adverse Event 
must be reported to the study sponsor by telephone within 24 hours of theevent. A Serious Adverse Event 
(SAE) form must be completed by the Investigator and faxed to theStudy Sponsor within 24 hours. The 
Investigator will keep a copy of this SAE form on file at thestudy site. Report Serious Adverse Events by 
phone and fax/email to: 
Phone: +41(0)91.640.42.50  
email: Corporate_drug_safety@sintetica.comAt the time of the initial report, the following information 
should be provided: 
1. Study identifier; 
2. Study Center; 
3. Patient number; 
4. A description of the event; 
5. Data of onset; 
6. Current status. 
Within the following 48 hours, the investigator must provide further information on the SeriousAdverse 
Event in the form of a written narrative. This should include a copy of the completedSerious Adverse Event 
form, and any other diagnostic information that will assist the understandingof the event. Significant new 
information on ongoing Serious Adverse Events should be providedpromptly to the Study Sponsor. 
11.STATISTICAL METHODOLOGY 
11.1 
Rationale for sample size calculation 
 
The size of this study is based on the A’Hern method for single stage phase II designs (35). 
We estimate as satisfactory a success rate of around 90% (p1=90%) or more, while a success rate of 80% 
(p0=80%) or less will be considered inadequate; following the A’Hern formula based on the exact binomial 
distribution and assuming an 80% power and alpha=0.05, the required sample size, for each group, is 82, 
with 72 being the minimum required number of successes to observe in order to  reach a conclusion in favour 
of the treatment’s efficacy. 
Expected drop out rate for the primary endpoint is low given that a single dose injection is requested, and 
assuming a 5% drop out rate 87 patients in each study arm shall be enrolled. In total 174 patients will be 
enrolled.  
In case of successful interim analysis we could consider, based on the same article and no other 
modifications in the hypothesis, a mayor power of 90%. In this case the required sample size for each group 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
34 
 
is 112 (97 success to observe) considering the drop out rate the patient enrolled in each arm are 118. In total 
236 patient will be enrolled   
Success rates and 95% CI will be presented separately for the two treatment groups, while a direct 
comparison will not be the focus of this study. 
11.2 
Study endpoints 
11.2.1 Primary efficacy endpoint 
 
The primary efficacy endpoint of the study will be represented by the overall proportion of patients, in each 
of the two dosage level groups, not requiring rescue anesthesia during surgery.  
11.2.2 Secondary efficacy endpoints 
 
The secondary efficacy endpoints of the trial will be evaluated, unless otherwise specified, on the two 
dosage level groups separately and, in both the two dosage level groups, on the two surgical procedures. 
Secondary efficacy endpoints will be: 
• 
Proportion of patients, in both of the two dosage level groups, not requiring rescue anaesthesia 
(fentanyl) during the two surgical procedures separately;  
• 
Time to onset of sensory block, defined as the time period from completion of the injection 
(time 0 min) to the achievement of complete sensory block,assessed by pin-prick test associated 
with heart rate measurement and evaluated for both surgeries; 
• 
Time to regression of motor block evaluated in ‘calcaneo stop’ surgery only and assessed by a 
grade I of the standard Bromage scale (i.e. free movement of legs and feet). This evaluation 
will be performedimmediately after the awakening and it will be repeated 30 minutes, 1 hour, 2 
hours and 3 hours after the first evaluation,as well as during the visit for discharge  
• 
Pain intensity evaluated five times in the first 3 hours after patient’s awakening and during the 
home discharge visit (V2). Post-surgery assessment will be performed immediately after the 
awakening and it will be repeated 30 minutes, 1 hour, 2 hours and 3 hours after the first 
evaluation. The technique and appropriate scale for pain measurement are age-dependent 
therefore, different tools will have to be used for the evaluation: 
− 
COMFORT scale for patients <2 months of age; 
− 
FLACC scale for patients aged  2 months  6 years; 
− 
Wong-Baker scale for patients over 6 years of age;  
• 
Time to eligibility for home discharge, defined as: “the time elapsed from completion of 
surgery to the time when criteria for discharge are met, regardless if the patient will be 
discharged from the hospital at a later time, according to the hospital procedures”. The criteria 
for discharge will be defined according with the Pediatric Post Anesthesia Discharge Scoring 
System (Ped-PADSS) 
• 
Time from completion of IMP injection to rescue anaesthesia, whenever required 
• 
Posology of rescue anaesthesia, whenever required 
• 
Proportion of patients requiring additional analgesia after surgery, other than paracetamol 15 
mg/kg i.v. administered during the surgery as per hospital’s standard procedures 
• 
Type and posology of rescue analgesia required during the 7 days after surgery for each one of 
the two surgical procedures 
 
 
 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
35 
 
11.2.3 Secondary safety endpoints 
 
The secondary safety endpoints of the trial will be evaluated on the two dosage level groups separately and, 
in both the two dosage level groups, on the two surgical procedures, and will be: 
 
• 
Patient general recovery, evaluated by the Investigator through the evaluation questionnaire on 
the day of the intervention  
• 
Patient general recovery, evaluated by the Investigator or his deputy through the F.U 24 H 
evaluation questionnaire on the day after intervention  
• 
Patient general recovery, evaluated by the Investigator or his deputy through the F.U 7-day 
evaluation questionnaire 7 days after intervention  
• 
Overall proportion and 95% CI of patients with prolonged post-operative temporary loss of 
sensation and/or motor activity 
• 
Vital signs at rest (heart rate, systolic/diastolic blood pressure, respiratory rate, body 
temperature) 
• 
Proportion of patients with AE, in each of the two dosage level groups and in the two surgical 
procedures  
• 
Summaries of adverse events (AEs), including pain at injection site, neurological symptoms 
(such as: convulsion) and cardiac symptoms (such as bradycardia and heart failure etc.) 
evaluated, during surgery, after IMP injection 
11.3 
Analysis sets 
 
The analysis of study medication efficacy and safety will be performed on two study populations: 
Intention to Treat (ITT; all all randomised patients who fulfil the study protocol requirements in 
terms of study anaesthetics administration) and Per Protocol (PP:all randomised patients who fulfil the 
study protocol requirements in terms of anaesthetic administration and primary efficacy evaluation, with no 
major deviations that could affect the primary efficacy results).  
 
11.4 
Description of statistical analysis 
 
11.4.1 Handling of missing data 
 
Missing data will be replaced by single imputation method (Last Observation Carried Forward (LOCF) 
which, in the present case, is adequate since the IMP is given only once to each participant and the overall 
observation period of each patient is limited to 7 days after administration of the investigational treatment. 
 
11.4.2 Primary efficacy variable 
 
Overall proportion of patients, in each of the two dosage level group, non-requiring additional anaesthesia 
for the duration of the surgical procedure will be presented together with 95% CI. 
 
11.4.3 Secondary efficacy variables 
 
Given the exploratory nature of the study, statistical evaluations will be mainly descriptive. 
Quantitative secondary endpoints will be summarized by means of descriptive statistics as total number of 
evaluated subjects, mean, standard deviation, 95% confidence interval, median, minimum and maximum and 
number of missing values. 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
36 
 
Categorical measures will be reported as frequency, percentages of observed values and 95% confidence 
interval. 
 
11.4.4 Safety variables 
 
Quantitative safety endpoints will be summarized by means of descriptive statistics as total number of 
evaluated subjects, mean, standard deviation, median, minimum and maximum and number of missing 
values. 
Categorical safety endpoints will be reported as frequency and percentages of observed values. 
AEs will be represented by frequency and percentage of patients with AE; AE will be summarized by the 
MedDRA System Organ Class (SOC) and Low Level Term (LLT), when calculating the number of AEs 
within each SOC and LLT, each subject will only be counted once. 
 
11.5 
Interim Analysis 
 
An interim analysis for efficacy and safety is foreseen when 87 patients (half of the expected study 
population) will have performed the second telephone follow up and completed the study.   
12.REGULATORY AND ETHICAL ISSUES 
12.1 
Compliance With Regulations Applicable To Clinical Trials 
 
The study will be conducted according to the laws, regulations and administrativeprovisionsrelating to the 
implementation of Good Clinical Practice in the conduct ofclinical trials on medicinalproducts for human 
use, as applicable by nationallegislation and EU Directives. The Investigator is responsible for the conduct of 
the trial at his/her site. He/she will ensure that the trial is performed in accordance with the clinical 
trialprotocol and with the ethical principles that have their origin in the Declaration of Helsinki, as well as 
with the ICH Note for Guidance on Good Clinical Practice (ICH Topic E6, 1996) and applicable regulatory 
requirements. In particular, the Investigator must ensure that only subjects whose written informed consent 
has been properly given are included into the trial. 
 
12.2 
Informed Consent and Child Assent Form 
 
A minor subject should not enter in a clinical study until the informed consent of the parents or legal 
representative has been obtained; consent must represent the minor's presumed will and may be revoked at 
any time, without detriment to the minor.Parents or legal representative have been properly informed and 
have freelygiven his/her consent by signing and dating two (2) original copies of the Informed Consent prior 
toperforming any study related procedures.One original copy will be given to the parent or legal 
representative and the second one will be maintened at the site,following the signature and dating by the 
Investigator. 
A copy of the proposed consent form must be submitted to the Ethics Committee (EC), togetherwith the 
Protocol, and other relevant documents for approval. 
Each parent or legal representative’s signed Informed Consent must be kept on file (in the study filesor 
patient file) by the Investigator for Regulatory Authorities inspection at any time. 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
37 
 
Study participants who, according to the investigator’s judgement, are old enough to understand what the 
study involves (predictable between the ages of 7 and 17) will be given the opportunity to assent to the study 
by means of a simple (no more than one page) document (in addition to the parental consent form) which 
will be written in a language appropriate to the child's age. This document shall be submitted to the IRB/EC 
for approval together with the parental ICF and will comply with relevant local requirements of each 
participating country/site. 
 
12.3 
Criteria for patient’s withdrawal 
 
Participants will be free to discontinue the trial at any time without giving their reasons. A participant must 
be withdrawn in the event of any of the following: 
− withdrawal of the subject’s consent. 
− discovery of ineligibility  
− administrative reasons  
If a subject has failed to attend scheduled trial assessments, the Investigator must determine the reasons and 
the circumstances as completely and accurately as possible. In case of premature withdrawal from the trial, 
the investigations scheduled for the last visit should be performed, if possible with focus on the most relevant 
assessments.In any case, the appropriate eCRF section must be completed. 
12.4 
Withdrawal from the Investigational Medicinal Product 
 
Not applicable (single-dose study) 
12.5 
Premature discontinuation of the trial 
 
The whole trial may be discontinued prematurely in the event of any of the following: 
− New information leading to unfavorable risk-benefit judgment of the IMP, e.g. due to: 
o Evidence of inefficacy of the IMP, 
o Occurrence of significant previously unknown adverse reactions or unexpectedly high 
intensity or incidence of known adverse reactions, or 
o Other unfavorable safety findings. 
− Sponsor’s decision that continuation of the trial is unjustifiable for medical or ethical reasons. 
− Poor enrollment of subjects making completion of the trial within an acceptable time frame unlikely. 
− Discontinuation of development of the Sponsor’s IMP. 
− Withdrawal of IMP(s) from the market for safety reasons. 
Health Authorities and Independent Ethics Committees (IECs)/Institutional Review Boards (IRBs) will be 
informed about the discontinuation of the trial in accordance with applicable regulations. The whole trial 
may be terminated or suspended upon request of Health Authorities. 
12.6 
Definition of end of the trial 
 
The study will terminate once all the enrolled participants (with the exception of properly documented drop-
out and lost to follow up) will have performed the telephone follow up call n. 2 (Day 7).  
 
 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
38 
 
12.7 
Regulatory Authorities and Ethics Committee (EC) 
 
The present protocol is part of an extensive Pediatric Investigational Plan (PIP) which has been submitted to 
the Paediatric Committee (PDCO) of the European Medicine Agency (EMA).The PDCO has adopted a 
positive opinion on both the overall research strategy and on the present clinical protocol. 
Before starting with the study operations, the clinical protocol must be approved in writing by an appropriate 
EC.Any amendments to the Protocol or subsequent changes to the Informed Consent as a result ofchanges to 
the Protocol, must be approved by the EC. Records of the EC review and approval of alldocuments 
pertaining to this study must be kept on file by the Investigator and are subject toRegulatory Authorities 
inspection during or after completion of the study. Unexpected andassociated SAEs must also be reported to 
the EC. 
12.8 
Protocol Amendments 
 
Changes to the Protocol should only be made by an approved protocol amendment.Protocol amendments 
must be approved by the Sponsor, Central EC and/oreach respectivesite’s EC (if applicable), prior to 
implementation. 
12.9 
Patient Confidentiality 
 
The Sponsor is concerned about the individual patient’s privacy and, therefore, all patient data willbe 
identified only by a subject identification number and subject name and date of birth code. Thedata will be 
blinded correspondingly in all data analysis. 
However, it is required that the Investigator will permit, after receiving patient’s approval, the studymonitor, 
independent auditor or regulatory agency personnel (with or without the Investigator) to review that portion 
of the patient’s medical record that is directly related to the study. 
12.10 
Clinical Trial Insurance 
 
Adequate insurance coverage for all subjects of all countries participating in the trial will be 
supplied by the Sponsor. Insurance conditions will meet the relevant local laws and regulations. 
13.DOCUMENTATION 
13.1 
Site Documents Required 
 
Prior to the initiation of the study, the following items must be received by the Sponsor: 
1. Letter 
of 
EC 
approval 
for 
the 
Protocol, 
amendments 
(if 
applicable), 
Informed 
Consent,advertisements (if applicable), Membership list; 
2. A signed copy of the Protocol, amendments and notifications (if applicable); 
3. The Investigator’s curriculum vitae as well as the curriculum vitae of any Co-Investigator(s); 
4. A list of the persons involved with the study and their signatures; 
5. Study site agreement(s); 
6. Health regulatory approval (where applicable); 
7. Local laboratory certification and normal ranges (if applicable). 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
39 
 
13.2 
Site Documents Supplied By The Sponsor 
 
Prior to the initiation of the study, the Sponsor will supply the Investigator with the following itemsin 
addition to the Protocol: 
1. Procedure and credential for the access to the electronic Case Report Forms; 
2. Operations Manual (inclusive of e-CRF manual); 
3. Model of Informed Consent; 
4. Current version of the Investigator’s Brochure and/or Product Monograph; 
5. Regulatory Binder 
6. IMP Manual. 
13.3 
Maintenance And Retention Of Records 
 
The Study will be conducted according to Good Clinical Practices. It is the responsibility of theInvestigator 
to maintain a comprehensive and centralized filing system of all relevantdocumentation. All original subject 
files (medical records) must be stored at the site for the longest possible time permitted by the applicable 
regulations, and/or as per ICH GCP guidelines, whichever is longer. In any case, the Investigator  will be 
instructed to consult with the Sponsor before disposal of any study recordand to notify the Sponsor of any 
change in the location, disposition or custody of the study files. 
13.4 
Case Report Form (Crf) 
 
Electronic CRFs (eCRFs) for individual patients will be used in the frame of this study.eCRFs are used to 
record study date and are an integral part of the study and subsequent reports.It is the Investigator’s 
responsibility to ensure the accuracy and completeness of the data entered in the eCRFs. The data will be 
entered into a validated database. CRO Data Managementwill be responsible for data processing, in 
accordance with the Sponsor’s data management procedures. Database lock will occur once quality control 
procedure, and quality assurance procedures have been completed. PDF files of the eCRFs will be provided 
to the Investigators at the completion of the trial. 
Source documents for this study such as the clinic chart or tests are to be maintained in a studybinder.eCRFs, 
source documents and copies of test results must be available at all times for inspection bythe study monitor, 
Sponsor, CRO and Regulatory Authority. 
13.5 
Source Data and Subject Files 
 
The Investigator must keep a subject file (medical file, original medical records) on paper or electronically 
for every subject included in the trial. This file will contain the available demographic and medical 
information for the subject, and should be as complete as possible. In particular, the following data should be 
available in this file:  
 
− Subject’s and parents’ (or tutor’s) full name, 
− Date of birth, 
− Sex, 
− Height, 
− Weight, 
− Medical history and concomitant diseases, 
− Prior and concomitant therapies (including changes during the trial), 
− Trial identification (Sponsor’s trial number according to clinical trial protocol), 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
40 
 
− Date of subject’s inclusion into the trial (i.e. date of giving informed consent), 
− Subject number in the trial, 
− Dates of the subject’s visits to the site and of telephone follow-up calls, 
− Any medical examinations and clinical findings predefined in the clinical trial protocol, 
− All adverse events observed in the subject, 
− Date of subject’s end of trial, 
− Date of and reason for early withdrawal of the subject from the trial or from IMP, if relevant. 
It must be possible to identify each subject by using this subject file. Additionally, any other documents 
containing source data must be filed (e.g., ECG trace and report, completed scales and questionnaires). Such 
documents must bear at least the subject number and the date when the procedure was performed.  
13.6 
Monitoring 
 
The study monitor will be responsible for coordinating the activities of the study monitoring team toensure 
adherence to ICH guidelines and the standard operating procedures.Experienced Monitors from CRO will be 
trained to monitor the study. The Monitors will be trainedon ICH GCP Guidelines, trial-specific SOPs, study 
protocol and the study monitoring convention. 
These visits are for the purposes of verifying adherence to the Protocol and the completeness andexactness of 
data entered on the eCRF. The study monitor will verify eCRF entries by comparingthem with the primary 
source document which will be madeavailable for this purpose. The Monitor will review the progress of the 
study with the Investigatorand other site personnel on a regular basis. At the end of the study, a Closure 
Monitoring Visit willbe performed. Monitoring visits will be arranged in advance with site personnel at a 
mutuallyacceptable time. Sufficient time must be allowed by the site personnel for the Monitor to 
reviewCRFs and relevant source documents. The Coordinator and/or Investigator should be available 
toanswer questions or resolve data clarifications. Adequate time and space for these visits will bemade 
available by the Investigator. 
13.7 
Protocol Modifications 
 
The procedures defined in the Protocol and in the e-CRFs will be carefully reviewed to ensure that allparties 
involved with the study fully understand the Protocol. In order to ensure the validity of thedata, with minimal 
exceptions, no deviations from the Protocol may be made unless waived by theSponsor depending upon the 
magnitude of the deviation. If the issue is broad enough to warrantrevision of the Protocol, such revisions 
must be submitted to and have approval in writing from theSponsor, and the EC prior to implementation at 
the site. 
13.8 
Audit/Inspection 
 
The study may be inspected by regulatory agencies. These inspections may take place at any timeduring or 
after the study and are based on the local regulations.The purpose of the Audit is to determine whether or not 
the study is being conducted and monitoredin compliance with recognized GCP guidelines or laws and study 
protocol. 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
41 
 
14.USE OF INFORMATION AND PUBLICATION 
14.1 
Confidential Information 
 
Confidential information refers to any information provided by the Sponsor. This includes,but is not limited 
to, the clinical protocol (and protocol amendments, if any), eCRFs, assay or studymethods and basic 
scientific data. Any data collected during the study should also be consideredas confidential. 
14.2 
Clinical Trial Report 
 
After completion of the trial, a clinical trial report according to ICH Topic E3 will be written by the 
Sponsor/CRO. 
14.3 
Publication policy 
 
The Investigator will inform the Sponsor in advance about any plans to publish or present data from the trial. 
Any publications and presentations of the results (abstracts in journals or newspapers, oral presentations, 
etc.), either in whole or in part, by Investigators or their representatives will require pre-submission review 
by the Sponsor. 
The Sponsor will not suppress or veto publications, but maintains the right to delay publication in order to 
protect intellectual property rights. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
42 
 
15.INVESTIGATOR’S AGREEMENT 
 
I have carefully read the foregoing Protocol and agree that it contains all the necessary informationfor 
conducting this study safely. I will conduct this study in strict accordance with this Protocol andwill attempt 
to complete the Study within the time designated. 
I will provide copies of the Protocol and all other information to all personnel responsible to mewho 
participate in the study. I will discuss this information with them to assure that they areadequately informed 
regarding the drugs and conduct of the study. 
I agree to keep records on all subject information (CRFs, shipment and drugs return forms and allother 
information collected during the study) in accordance with GCP and local regulations. 
 
__________________________________  
 
 
__________________________________ 
Investigator’s signature  
 
 
 
 
Sponsor signature 
 
Date: ____________________________  
 
 
Date: ____________________________ 
 
 
Name ____________________________  
 
 
Name____________________________ 
(please use capital letters or stamp)  
 
 
 
(please use capital letters or stamp) 
 
 
 
 
 
 
 
 
 
 
 
PROTOCOL TITLE 
Randomized, multi-center, double-blind, two-armed, parallel active groups, prospective trial, to evaluate, in 
pediatric population undergoing 'Calcaneo stop' surgery or Inguinal hernia repair, the efficacy and safety of 
chloroprocaine 1% and 2% for peripheral nerve block based on concentration–response relationships. 
 
 
 
 
 
 
 
 
 
 
 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
43 
 
16.REFERENCES 
 
1. Giorgio Veneziano, Peter Iliev, Jennifer Tripi, David Martin, Jennifer Aldrink, Tarun Bhalla, Joseph 
Tobias. Continuous chloroprocaine infusion for thoracic and caudal epidurals as a postoperative 
analgesia modality in neonates, infants, and children. Pediatric Anesthesia 26 (2016) 84–91 
2. David M. Polaner, Andreas H. Taenzer, Benjamin J. Walker, Adrian Bosenberg, Elliot J. Krane, 
Santhanam Suresh, Christine Wolf, Lynn D. Martin. Pediatric Regional Anesthesia Network 
(PRAN): A Multi- Institutional Study of the Use and Incidence of Complications of Pediatric 
Regional Anesthesia. Anesth Analg 2012;115: 1353–64 
3. Joseph D Tobias et al. Chloroprocaine for epidural anaesthesia in infabnts and children. Journal of 
the American association of Nurse Anesthesists, 1995(69) 2: 131 -135 
4. Christopher M. Bernards, Admir Hadzic, Santhanam Suresh, Joseph M. Neal. Regional Anesthesia 
in Anesthetized or Heavily Sedated Patients. Regional Anesthesia and Pain Medicine, 2008(33) 5: 
449–460 
5. R. D. Shah and S. Suresh. Applications of regional anaesthesia in paediatrics. British Journal of 
Anaesthesia 2013 (111) (S1): 114– 124  
6. William A. Catteral, Kennet Mackie. Goodman and Gilman’s “The pharmacological basis of 
therapeutics” 2011. Local Anesthetics - chapt 14 (369 – 86) 
7. Benjamin G. Covino, Donald B. Gjddon. Pharmacology of Local Anesthetic Agents. J Dent Res 
1981. 60(8):1454-1459 
8. C. L. Jeng, T. M. Torrillo and M. A. Rosenblatt. Complications of peripheral nerve blocks. British 
Journal of Anaesthesia 2010. 105 (S1): i97–i107 
9. Kristine Henderson, Navil F. Sethna, Charles B. Berde. Continuous Caudal Anesthesia for Inguinal 
Hernia Repair in Former Preterm Infants. J. Clin. Anesth. 1993(5): 129 – 133 
10. Joseph D Tobias et al. Continuous regional anaesthesia in infants. Can J Anaesth 1993(40) 11: 1065-
1068 
11. Robert M Maccani et al. Femoral and lateral femoral cutaneous nerve block for muscle biopsies in 
children. Paediatric Anaesthesia 1995 (5): 223 – 227 
12. Tobias JD, Rasmussen GE, Holcomb GW , Brock JW , Morgan WM  Continuous caudal anaesthesia 
with chloroprocaine as an adjunct to general anaesthesia in neonates.Can J Anaesth. 1996 
Jan;43(1):69-72. 
13. Joel B. Gunter. Benefit and Risks of Local Anesthetics in Infants and Children. Pediatr Drugs 2002; 
4 (10): 649-672 
14. P. Marhofer, C. Sitzwohl, M. Greher and S. Kapral. Ultrasound guidance for infraclavicular brachial 
plexus anaesthesia in children. Anaesthesia, 2004, 59, pages 642–646 
15. U. Oberndorfer, P. Marhofer, A. Bosenberg, H. Willschke, M. Felfernig, M. Weintraud, S. Kapral 
and S. C. Kettner. Ultrasonographic guidance for sciatic and femoral nerve blocks in children. 
British Journal of Anaesthesia 98 (6): 797–801 (2007) 
16. H. Willschke, MD, A. Bosenberg, MBChB, FFA(SA), P. Marhofer, MD, S. Johnston, MBChB, 
FCA(SA), S. Kettner, MD, U. Eichenberger, MD, O. Wanzel, MD, and S. Kapral, MD. 
Ultrasonographic-Guided Ilioinguinal/Iliohypogastric Nerve Block in Pediatric Anesthesia: What is 
the Optimal Volume? AnesthAnalg2006;102:1680–4 
17. G. Ivan1 MD, G. Mattioli MD, M. Rega MD, A. Conio MD, V. Jasonni MD, P. De Negri MD. 
Clonidine-mepivacaine mixture vs plain mepivacaine in paediatric surgery. Paediatric Anaesthesia 
2996 6: 111-114 
18. Vrushali Ponde, Ankit P. Desai & Dipal Shah. Comparison of success rate of ultrasound-guided 
sciatic and femoral nerve block and neurostimulation in children with arthrogryposis multiplex 
congenita: a randomized clinical trial. Pediatric Anesthesia 23 (2013) 74–78 
19. D. Faraoni MD et al. Does ultrasound guidance improve the efﬁcacy of dorsal penile nerve block in 
children? Pediatric Anesthesia 2010 20: 931–936 
20. Santhanam Suresh, MD, and Melissa Wheeler, MD. Practical Pediatric Regional Anesthesia. New 
concepts and techniques in pediatric anesthesia. Volume 20 • Number 1 • March 2002 
21. Peter Marhofer, Giorgio Ivani, Santhanam Suresh, Estela Melman, Guadalupe Zaragoza & Adrian 
Bosenberg. Everyday regional anesthesia in children. Pediatric Anesthesia 22 (2012) 995–1001 
22. G. Ivani, V. Mossetti. Pediatric regional anesthesia. Minerva Anestesiologica Vol. 75 - No. 10. 577-
83 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
44 
 
23. Micic S., Horvat M., Komen Usljebrka H., Frkovic V., Azman J., Poldan Grabar N. Ultrasound 
guided popliteal sciatic nerve block vs. multimodal analgesia for postoperative pain control 
following calcaneo-stop surgery in children. European Journal of Anaesthesiology 2011, 28:206 
24. Vito Pavone, Luciano Costarella, Gianluca Testa, Giorgio Conte, Maria Riccioli,Giuseppe Sessa. 
Calcaneo-stop Procedure in the Treatment of the Juvenile Symptomatic Flatfoot. / The Journal of 
Foot & Ankle Surgery 52 (2013) 444–447 
25. Mary L. Brandt. Pediatric Hernias. Surg Clin N Am 88 (2008) 27–43 
26. Qayyum F, Alvear D (2017) Management of Inguinal Hernias in Premature Infants- Pre or Post 
Discharge- What Is Best? J Pediatr Neonatal Care 7(1): 00275. DOI: 10.15406/jpnc.2017.07.0027 
27. Bromage PR. Epidural analgesia. W.B. Saunders Co. 1978. page 144. 
28. Ambuel B, Hamlett KW, et al. Assessing distress in pediatric intensive care environments: The 
COMFORT scale. J Pediatric Psychology. 1992; 17: 95-109. 
29. Merkel, S. I., Voepel-Lewis, T., Shayevitz, J. R., & Malviya, S. (1997). The FLACC: A behavioral 
scale for scoring postoperative pain in young children. Pediatric Nursing, 23(3), 293–297. 
30. Wong-Baker FACES Foundation (2016). Wong-Baker FACES® Pain Rating Scale. 
31. Biedermann S, Wodey E, De La Briere F et al. Paediatric discharge score in ambulatory surgery. 
Ann Fr Anesth Reanim 2014; 33: 330–334. 
32. Moncel JB, Nardi N, Wodey E, Pouvreau A, Ecoffey C (2015). Evaluation of the pediatric post 
anesthesia discharge scoring system in an ambulatory surgery unit. Pediatric Anesthesia 25 (2015) 
636–641 
33. Chung F. Are discharge criteria changing? J Clin Anesth 1993; 5(6 Suppl 1): 64S–68S 
34. Chung F. Discharge criteria – a new trend. Can J Anaesth 1995; 42: 1056–1058.. 
35. R. P. A'Hern, Sample size tables for exact single-stage phase II designs, Statistics In Medicine 
Statist. Med. 2001; 20:859-866 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol CHL.2/04-2015 
 
 
 
 
 
EudraCT number: 2018-000656-18 
Final Version 1.0 - 14/Jun/2018 
45 
 
17. LIST OF APPENDICES 
 
17.1 Declaration of Helsinki 
17.2 FLACC scale (sample) 
17.3 COMFORT scale (sample) 
17.4 WONG-BAKER scale (sample) 
17.5 Questionnaires(24h – 7days) 
17.6 Patient diary